Document:

Management Bonus Program 2005

 Exhibit 10.1 
  
 SONIC INNOVATIONS, INC. 
 Management Bonus Program 
 2005 
  
 MANAGEMENT BONUS PROGRAM 
  
 The Management Bonus Program (“the Program”) is designed to reward senior level managers for achieving specified Company performance goals and individual
performance objectives. The Program’s objective is to motivate such senior level managers by providing an annual cash bonus opportunity. 
  
 PROGRAM SUMMARY 
  
 The Compensation Committee of the Board of Directors administers the Program. Funding for the Program is based on the performance of the Company for the year. Bonuses are calculated and distributed during the first
quarter of the subsequent year, following audit of the Company’s full year results. 
  
 Bonuses are based on achievements of goals in three segments: the Company’s annual sales goal, the Company’s annual earnings per share goal, and individual performance goals. The three segments, equally
weighted at one-third each, are independent. Under-achievement in one of them may reduce that segment’s bonus to zero, but would not affect the other two segments. Similarly, over-achievement in one segment may increase that portion of the
bonus without affecting the other segments. 
  
 TARGETS 
  
 Targets for sales and earnings per share will be based on the Company’s operating plan
and will be approved by the Compensation Committee of the Board of Directors. 
  
 BONUS LEVELS FOR ACHIEVEMENT OF PLAN 
  
 A “base bonus”
will be paid ithe targets in the three segments are met. Base bonus levels for participants may vary by title and position. A listing of participants and their base bonus levels is recommended annually by the Chief Executive Officer
(“CEO”) and approved by the Compensation Committee of the Board of Directors. Base salary means compensation paid during the Program year, excluding commissions, special awards and perquisites. 
  
 Actual sales and earnings per share will be as reflected in the Company’s audited
financial statements. Participant’s objectives will be measurable, quantifiable and agreed to beforehand. The CEO will make the final determination of the degree of achievement for the other executives, and the Chairman of the Board of
Directors will make the determination for the CEO. 
  
 OVER-ACHIEVEMENT OF PLAN

  
 If the sales and/or the earnings per share numbers are better than the
“at target” figures, the bonus for that segment will increase. Over-achievement of a participant’s individual goals may result in an increased bonus for that segment as well. 
  
 UNDER-ACHIEVEMENT OF PLAN 
  
 If the sales and/or the earnings per share numbers are worse than the “at target”
figures, the bonus for that segment will decrease. There will be an appropriate decrease in bonus for under-achievement in the individual objectives segment as well. Under-achievement in any one segment may not result in forfeiture of more than 33
1/3% of a participant’s base bonus. 
  

 ELIGIBILITY 
  
 Participation in the Bonus Program will be recommended by the CEO and approved by the Compensation Committee of the Board of Directors. New employees hired during the
year may be eligible to participate on a pro rata basis. Employees promoted during the year may be eligible to participate or participate at a higher award level, on a pro rata basis. 
  
 TERMINATION OF EMPLOYMENT 
  
 In the event that any participant shall cease to be a full-time employee during any year in which he/she is participating in the Program, that participant will not be
entitled to a bonus payment for that Program year. 
  
 AMENDMENT OF THE PROGRAM

  
 The Compensation Committee of the Board of Directors may, from time to
time, make amendments to the Program, as it believes appropriate, and may terminate the Program at any time. 
  
 MISCELLANEOUS 
  
 Nothing contained in the
Program shall be construed to confer upon any participant any right to continue in the employ of the Company or affect in any way the Company’s right to terminate a participant’s employment at any time. 
  
 SALES SEGMENT BONUS 
  
 The bonus for the segment measured by the Company’s net sales target will be 33 1/3% of the participant’s base bonus, adjusted for
over/under-achievement per the schedule below. For every 1% increase in sales above target, the bonus increases by 5% of base bonus, without upper limit. For every 1% shortfall below target, the bonus decreases by 5% of base bonus, but below 94% of
target it falls to zero. The bonus for this segment cannot be less than zero. 
  

					
	 Net Sales

	  	% of Target

	 	% of Base Bonus

	 	  	<94%	 	No Bonus
	 -6%
	  	94%	 	3.3%
	 -5%
	  	95%	 	8.3%
	 -4%
	  	96%	 	13.3%
	 -3%
	  	97%	 	18.3%
	 -2%
	  	98%	 	23.3%
	 -1%
	  	99%	 	28.3%
	 Target
	  	100%	 	33.3%
	 1%
	  	101%	 	38.3%
	 2%
	  	102%	 	43.3%
	 3%
	  	103%	 	48.3%
	 4%
	  	104%	 	53.3%
	 5%
	  	105%	 	58.3%
	 No Limit
	  	 	 	No Limit

  

 EPS SEGMENT BONUS 
  
 The bonus for the segment measured by the Company’s earnings per share will be 33 1/3% of the participant’s base bonus, adjusted for over/under-achievement per
the schedule below. For every $0.01 increase in earnings per share above target, the bonus increases by 5% of base bonus, without upper limit. For every $0.01 shortfall below target, the bonus decreases by 5% of base bonus, but below $0.07 of
targeted earnings per share the bonus falls to zero. The bonus for this segment cannot be less than zero. 
  

			
	 Earnings Per Share

	  	% of Base Bonus

	 -$0.07
	  	No Bonus
	 -$0.06
	  	3.3%
	 -$0.05
	  	8.3%
	 -$0.04
	  	13.3%
	 -$0.03
	  	18.3%
	 -$0.02
	  	23.3%
	 -$0.01
	  	28.3%
	 Target
	  	33.3%
	 $0.01
	  	38.3%
	 $0.02
	  	43.3%
	 $0.03
	  	48.3%
	 $0.04
	  	53.3%
	 No Limit
	  	No Limit

  

 INDIVIDUAL PERFORMANCE SEGMENT BONUS 
  
 The CEO and each Program participant will mutually agree upon a set of objectives, whose accomplishment will determine the bonus level for
this segment: 
  

			
	 OBJECTIVE

	 	 ACHIEVEMENT LEVEL (%)

	 1.
	 	 
	 2.
	 	 
	 3.
	 	 
	 4.
	 	 

  
 Under-achievement of objectives will
result in a reduction in bonus for this segment. Over-achievement should be rare, since the goals will be set high. Should over achievement occur, the bonus may increase. 
  
 If three objectives are used, 11.1% of the participant’s base bonus will be awarded for the achievement of each objective. If all three
objectives are achieved, the total award for this segment will be 33 1/3% of the participant’s base bonus. 
  
 If four objectives are used, 8.3% of the participant’s base bonus will be awarded for the achievement of each objective. If all four objectives are achieved, the
total award for this segment will be 33 1/3% of the participant’s base bonus. 
  

																	
						
	 Objectives approved:
	 	 	 	 	 	Date:	 	 	 	 
	 (Program Participant)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
						
	 Objectives approved:
	 	 	 	 	 	Date:	 	 	 	 
	 (Chief Executive Officer)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
						
	 Achievement level approved:
	 	 	 	 	 	Date:	 	 	 	 
	 (Chief Executive Officer)Development and Supply Agreement

 Exhibit 10.1 
  
 SEATTLE GENETICS, INC. 
 DEVELOPMENT AND SUPPLY AGREEMENT 
  
 This Development and Supply Agreement (the “Agreement”) is entered into this 18th day of February, 2005 (“Effective Date”) by and between Abbott Laboratories, an Illinois corporation
having a principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500 (“Abbott”), and Seattle Genetics, Inc. having a principal place of business at 21823 – 30th Drive Southeast in Bothell, Washington 98021
(“Seattle Genetics”). 
  
 WHEREAS, Seattle
Genetics is the owner of certain technology and patent rights regarding compounds incorporating humanized S2C6 anti-CD40 monoclonal antibodies, which are used as drugs for cancer and other diseases; 
  
 WHEREAS, Seattle Genetics intends to file for approval with the United States
Food and Drug Administration (and its foreign equivalents), Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and/or Biologics License Applications (BLAs) (and their foreign equivalents), for certain formulations containing
Bulk Drug Substance, as defined below; 
  
 WHEREAS, Seattle
Genetics has certain process information relating to Bulk Drug Substance and desires to have Abbott evaluate such information and to scale-up and adapt the current manufacturing process for the preparation of Bulk Drug Substance at Abbott
facilities; 
  
 WHEREAS, Abbott possesses process engineering
capabilities and operates process development facilities, which include small scale bulk drug substance laboratories and pilot plants, as well as large scale facilities for the manufacture of clinical and commercial quantities of certain bulk drug
substances; 
  
 WHEREAS, Abbott desires to evaluate Seattle
Genetics’ process information and scale-up and adapt the current manufacturing process for the preparation of Bulk Drug Substance at Abbott facilities; and 
  

WHEREAS, Abbott desires to manufacture for Seattle Genetics, developmental, clinical and commercial quantities of Bulk Drug Substance, and Seattle
Genetics desires to purchase from Abbott such quantities, all subject to the terms and conditions of this Agreement. 
  
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties hereto agree as follows:

  
 1. Definitions 
  
 As used in this Agreement, the following words and phrases shall have the
following meanings: 
  
 1.1 “Abbott Inventions” means
any ideas, innovations or inventions related to manufacturing (whether or not patentable) developed by Abbott, Abbott’s Affiliates, Abbott and 
  

	
	  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of
this exhibit has been filed separately with the Securities and Exchange Commission.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	1	  	 

 Third Parties, or Abbott’s Affiliates and Third Parties, prior to or during the Term, including, without limitation,
Abbott Know-How and Abbott Patent Rights. 
  
 1.2 “Abbott
Know-How” means all unique, confidential, proprietary non-patented technical data, drawings, and related documentation, including all improvements thereto, not included in Abbott Patent Rights, as defined below, that describe the process of
manufacturing the Bulk Drug Substance as developed by Abbott for Seattle Genetics during the Project that is either (a) owned by Abbott, or Abbott’s Affiliates, or licensed to Abbott, with the right to sublicense, as of the Effective Date, (b)
generated by Abbott without Seattle Genetics’ participation during the Term, or (c) acquired by Abbott (other than from or on behalf of Seattle Genetics) during the Term 
  
 1.3 “Abbott Patent Rights” means United States and foreign patents and patent applications, including divisions,
continuations, continuations-in-part, additions, renewals, extensions, re-examinations and reissues of all such patents and patent applications, all as are owned by Abbott, or Abbott’s Affiliates, or licensed by Abbott, with the right to
sublicense, and to which Seattle Genetics would need a license in order to practice the manufacturing and/or process development operations relating to the manufacture of Bulk Drug Substance as developed by Abbott for Seattle Genetics during the
Project. 
  
 1.4 “Affiliate” of a Party hereto means any
entity that controls, is controlled by, or is under common control with such Party. For purposes of this definition, a Party shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of
the voting equity of the other entity (or other comparable ownership interest for an entity other than a corporation). For purposes of this Agreement, TAP Pharmaceutical Products, Inc. shall be excluded from the definition of Abbott’s
Affiliates. 
  
 1.5 “Applicable Dollar Volume” means as
such term is defined in Section 10.2. 
  
 1.6 “Batch
Records” means the mutually agreed upon final batch production and control records for the Bulk Drug Substance prepared in accordance with 21 C.F.R. §211.188. 
  
 1.7 “BLA” means the Biologics License Application (or its foreign equivalent) filed with the FDA (or foreign
Regulatory Authority), seeking authorization to market Product in the United States (or applicable foreign country within the Territory). 
  
 1.8 “Bulk Drug Pricing” means as such term is defined in Exhibit D. 
  
 1.9 “Bulk Drug Substance” means the bulk form of the humanized S2C6 anti-CD40 monoclonal antibody, as more fully
described in Exhibit A, manufactured in accordance with this Agreement and meeting the Bulk Drug Substance Specifications. 
  
 1.10 “Bulk Drug Substance Specifications” means the written specifications for Bulk Drug Substance set forth in Exhibit B, as may be modified
from time to time pursuant to Section 8.2. 
  
 1.11 “Bulk
Drug Substance Storage Rate” means the rate of [***] per month per manufactured lot, provided that any fractional lots shall be considered a whole lot. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	2	  	 

 1.12 “cGMP” means the FDA’s current good manufacturing practices, as first published in
the Federal Register and then specified in the Code of Federal Regulations and FDA’s guidance documents, applicable to the manufacture of Bulk Drug Substance and all successor regulations and guidance documents thereto, as well as the
comparable practices, regulations and documents of any other comparable Regulatory Authorities, as in effect from time to time. 
  
 1.13 “CMC” means the Chemistry, Manufacturing and Controls section of the BLA. 
  
 1.14 “Calendar Quarter” means a three (3) month period commencing January 1, April 1, July 1 and October 1.

  
 1.15 “Confidential Information” means all
information, including, but not limited to, Seattle Genetics Inventions and Abbott Inventions disclosed pursuant this Agreement (before or after the Effective Date) in writing (or all information disclosed orally, visually and/or in another
intangible form which is summarized in writing as to its general content within thirty (30) days after original disclosure and identified as being confidential, provided however, that all information disclosed orally, visually and/or in another
intangible form by Abbott to Seattle Genetics during a site visit shall be considered “Confidential Information” of Abbott regardless of whether Abbott has summarized in writing as to its general content within thirty (30) days after
original disclosure and identified as being confidential and all information disclosed orally, visually and/or in another intangible form by Seattle Genetics relating to the process for Bulk Drug Substance to Abbott shall be considered
“Confidential Information” of Seattle Genetics regardless of whether Seattle Genetics has summarized in writing as to its general content within thirty (30) days after original disclosure and identified as being confidential), except any
portion thereof that: 
  

	 	(a)	is already known to the recipient upon receipt, as evidenced by its written records; 

  

	 	(b)	is disclosed to the recipient without restriction after acceptance of this Agreement by a Third Party who has the right to make such disclosure; or 

  

	 	(c)	is independently developed by or for the recipient without reliance on the Confidential Information, as evidenced by its written records; or 

  

	 	(d)	is or becomes available to the general public without fault of the recipient. 

  

1.16 “Contract Year” means [***]. A Contract Year shall end upon the termination of this Agreement regardless of the actual calendar date.

  
 1.17 “Convicted Individual” or “Convicted
Entity” means an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §1320a – 7(a), but has not yet been excluded, debarred, suspended or otherwise declared
ineligible. 
  
 1.18 “Debarred Entity” means a
corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from submitting or assisting in the 
  
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	3	  	 

 submission of any abbreviated drug application, or an employee, partner, shareholder, member, subsidiary or affiliate of
a Debarred Entity. 
  
 1.19 “Debarred Individual” means
an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from providing services in any capacity to a person that has an approved or pending drug product application, or an employer, employee or partner of a
Debarred Individual. 
  
 1.20 “Dedicated Equipment”
means as such term is defined in Section 8.11. 
  
 1.21
“Deficiency Notice” means as such term is defined in Section 9.8(a). 
  
 1.22 “EMEA” means the European Medicines Evaluation Agency, or any successor entity thereto having substantially the same functions. 
  
 1.23 “Excluded Individual” or “Excluded Entity” means (i) an individual or entity, as applicable, who
has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or
(ii) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the U.S. General Services
Administration (GSA). 
  
 1.24 “FDA” means the United
States Food and Drug Administration, or any successor entity thereto having substantially the same functions. 
  
 1.25 “First Commercial Sale” means [***] by Seattle Genetics, its Affiliates, subsidiaries, licensees, sublicensees, contractors, or other
designee to any Third Party for use or consumption of such Product in such country by the general public. 
  
 1.26 “Force Majeure Event” means as such term is defined in Article 19. 
  
 1.27 “Fully Burdened Manufacturing Cost” means the sum of the following costs to the extent reasonably and
properly allocable to the manufacture of Bulk Drug Substance: the cost of [***]. Fully Burdened Manufacturing Cost shall be calculated in a manner consistent with Generally Accepted Accounting Principles consistently applied. 
  
 1.28 “ICH” means the International Convention on Harmonisation and
any successor agreements and/or amendments thereto. 
  
 1.29
“Incurred Fees” means as such term is defined in Section 12.7(f). 
  
 1.30 “Initial Order Date” means as such term is defined in Section 9.3. 
  
 1.31 “Launch Date” means the date on which the First Commercial Sale of Product is made in the Territory by Seattle Genetics, its Affiliates,
subsidiaries, licensees, sublicensees, contractors, or other designee. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	4	  	 

 1.32 “Liability” means any liability, judgment, loss, damage, cost and other expense (including
reasonable attorney’s fees). 
  
 1.33 “Maximum Quarterly
Capacity” means [***] Bulk Drug Substance per Calendar Quarter of each Contract Year. 
  
 1.34 “Party” means either Abbott or Seattle Genetics individually; “Parties” means Abbott and Seattle Genetics together. 
  
 1.35 “Payment Schedule” means as such term is defined in Exhibit C, which Payment Schedule may be revised from
time to time by mutual written agreement of the Parties. 
  
 1.36
“Product” means any pharmaceutical product containing Bulk Drug Substance as its active ingredient. 
  
 1.37 “Project” means a multi-stage (each a “Stage”) project to adapt and further develop Seattle Genetics’ current process
for the manufacture of Bulk Drug Substance to Abbott’s manufacturing facility and develop such process to commercial scale so as to manufacture Bulk Drug Substance in compliance with this Agreement, as more fully described in the Project plan
set forth in Exhibit C. 
  
 1.38 “Project Schedule”
means the schedule for the work and Stages to be completed for the Project set forth in Exhibit C and as may be revised and modified over time as agreed to in writing by the Parties. 
  
 1.39 “Purchase Order” means any order instructions, including quantity of Bulk Drug Substance ordered, delivery
date, and shipping instructions, submitted by Seattle Genetics for supply of Bulk Drug Substance, subject to Section 9.7. In the event of any terms of the Purchase Order conflict with or are inconsistent with the terms of this Agreement, the terms
of this Agreement shall govern and control. 
  
 1.40 “Quality
Agreement” means as such term is defined in Section 8.7. 
  
 1.41 “Reassignment Costs” means as such term is defined in Section 12.7(f). 
  
 1.42 “Regulatory Authority(ies)” means the FDA, the EMEA, the ICH, or any comparable national or territorial regulatory entity within the Territory having substantially the same functions. 
  
 1.43 “Regulatory Filings” means the governmental filings required
to commence human clinical trials and to obtain approval to market Product in a given country within the Territory, including, but not limited to, Product registration(s) and marketing approval(s), as applicable, in each such country. 
  
 1.44 “Research and Development Fee” means as such term is defined
in Section 5.1. 
  
 1.45 “[***]” means as such term is
defined in Section 2.3. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	5	  	 

 1.46 “[***]” means as such term is defined in Section 2.3. 
  
 1.47 “Response Notice” means as such term is defined in Section
9.8(b). 
  
 1.48 “Rolling Forecast” means as such term
is defined in Section 9.4. 
  
 1.49 “Seattle Genetics
Know-How” means all unique, confidential, proprietary non-patented technical data, drawings, documentation, analytical and regulatory information and other information, including all improvements thereto, not included in Seattle Genetics Patent
Rights, as defined below, relating to the manufacture, use or sale of Bulk Drug Substance that is either (a) owned by Seattle Genetics (or Seattle Genetics’ Affiliates), or licensed to Seattle Genetics, with the right to sublicense, as of the
Effective Date, (b) generated by Seattle Genetics without Abbott’s participation during the Term, or (c) acquired by Seattle Genetics (other than from or on behalf of Abbott) during the Term. 
  
 1.50 “Seattle Genetics Patent Rights” means the United States
(listed on Exhibit G) and foreign patents and patent applications, including divisions, continuations, continuations-in-part, additions, renewals, extensions, re-examinations and reissues of all such patents and patent applications, all as are owned
by Seattle Genetics (or Seattle Genetics’ Affiliates), or licensed to Seattle Genetics, with the right to sublicense, claiming Bulk Drug Substance, or to which Abbott would need a license or sublicense in order to make Bulk Drug Substance.

  
 1.51 “Second Source” means as such term is defined
in Section 7.1. 
  
 1.52 “Stage” means as such term is
defined in Section 1.37. 
  
 1.53 “Term” means as such
term is defined in Section 12.1. 
  
 1.54 “Territory”
means the world. 
  
 1.55 “Third Party” or Third
Parties” means any person(s) or entity(ies), as applicable, other than the Parties, their Affiliates, or the Parties and Affiliates employees and agents. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	6	  	 

 2. Bulk Drug Substance Development Project 
  
 2.1 The Project. Following the Effective Date and according to technical reports and the project plan set forth in
Exhibit C, Abbott shall undertake the Project. The Project shall consist of research and development activities described on Exhibit C. Abbott shall perform its research and development activities hereunder pursuant to the terms of this Agreement
and the Project; provided, however, Seattle Genetics understands that, because the Project involves research from which the results are inherently uncertain, Abbott does not make [***] of any kind that the Project will result in a
commercially-viable process. Nevertheless, Abbott shall conduct the Project diligently and in accordance with generally accepted standards of good scientific practice including, but not limited to, the creation and maintenance of properly witnessed
complete and accurate laboratory notebooks made contemporaneous with the activities reflected therein. 
  
 2.2 Project Stages. At the completion of each Stage, except in the event that this Agreement is otherwise terminated as permitted herein, the
Parties shall mutually agree whether to (i) proceed with the Project; (ii) conduct further development work under the then current Stage in addition to those activities described in the Project for the then current Stage; or (iii) terminate this
Agreement. In the event that the Parties cannot agree on (i), (ii) or (iii) above, the Parties shall organize representatives with technical and executive decision making authority to meet in good faith and attempt to mutually agree on (i), (ii) or
(iii). If the Parties are unable to reach agreement at any Stage within ninety (90) days of initiating discussions, then either Party shall [***]. 
  
 2.3 Manufacturing Facility [***]. Abbott shall [***] for the [***] (as set forth in the Exhibit C hereto) [***] and Seattle Genetics agrees to pay
for [***], on the date [***] to the initiation of the [***] (payment currently estimated to occur on [***]) based on the then current Project Schedule, as may be revised by the Parties (the “[***]”). The [***] shall be [***] for the [***]
(the “[***]”) in accordance with the then current Project Schedule. Beginning on or around [***], Abbott shall initiate the manufacture of [***] cGMP [***] of Bulk Drug Substance meeting the Specifications. Once any such [***] occurs, and
the [***] in the [***] has passed, Abbott shall begin to [***] Seattle Genetics [***] according to the Payment Schedule. In the event that Seattle Genetics does not utilize the [***] to [***] the Project obligations, the [***] Seattle Genetics shall
[***] to Abbott shall be [***], to equal [***] of the [***] Abbott pursuant to this Section 2.3. Notwithstanding the foregoing, if Abbott is able to [***] for the [***], Abbott shall [***] Seattle Genetics with a reasonable [***] (as elected by
Seattle Genetics) in an [***] to be determined in good faith by Abbott. 
  
 3.
Abbott’s Research and Development Activities 
  
 3.1
Abbott’s Activities. One of the objectives of the Project shall be for Abbott to develop and manufacture Bulk Drug Substance and to support Seattle Genetics’ Regulatory Filings as appropriate, however, Seattle Genetics shall be
responsible for the preparation and filing of Regulatory Filings, and all communications with Regulatory Authorities, with respect to the Bulk Drug Substance. Abbott shall conduct and perform its obligations on the Project plan set forth in Exhibit
C as may be amended from time to time by mutual agreement of the Parties to achieve such objectives, including, but not limited to, the following: 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	7	  	 

	 	a.	Sourcing raw materials resins, disposable process components, reagents and testing supplies for use in manufacturing Bulk Drug Substance, provided that Seattle Genetics is
responsible for the cost of such raw materials; 

  

	 	b.	Performing pilot scale evaluation of Seattle Genetics’ manufacturing process; 

  

	 	c.	Adapting Seattle Genetics’ manufacturing process to Abbott’s equipment and systems; 

  

	 	d.	Developing optimized process parameters to manufacture Bulk Drug Substance in Abbott’s manufacturing facility; 

  

	 	e.	Preparing suitable manufacturing process documentation, including instructions and manufacturing controls for inclusion in Regulatory Filings; 

  

	 	f.	Provide the Bulk Drug Substance information directly to Seattle Genetics in support of Regulatory Filings, and assisting Seattle Genetics in responding to questions from Regulatory
Authorities concerning the manufacture of Bulk Drug Substance; 

  

	 	g.	Conducting material contact and cleaning validation studies, engineering and validation runs, process validation studies, and preparing process justification and validation summary
reports, in a mutually agreed upon timely manner, to meet pre-approval and other appropriate inspection requirements of the Regulatory Authorities and to support approval of the manufacture of the Bulk Drug Substance in an Abbott manufacturing
facility; 

  

	 	h.	Permitting Seattle Genetics to conduct all necessary cGMP and quality assurance reviews of Abbott documentation, including review and receipt of copies of Batch Records;

  

	 	i.	Permitting Seattle Genetics to access Abbott’s manufacturing data relating to Bulk Drug Substance; 

  

	 	j.	Providing Seattle Genetics with acceptable environmental impact statements, if required, for inclusion with Regulatory Filings; 

  

	 	k.	Providing Seattle Genetics with appropriate pilot and commercial scale batch record manufacturing documentation for Regulatory Filings and other uses in accordance with the Quality
Agreement; 

  

	 	l.	Preparation for and administration of the pre-approval inspection (and any other necessary inspections) by the Regulatory Authorities; and 

  

	 	m.	Subject to Section 2.1, manufacturing development supplies, clinical supplies and process validation batches of Bulk Drug Substance in accordance with current cGMPs and pursuant to
protocols to which the Parties shall mutually agree in writing. 

  

					
	 CONFIDENTIAL AGREEMENT
	  	8	  	 

 4. Seattle Genetics’ Research and Development Activities 
  
 4.1 Seattle Genetics’ Activities. Seattle Genetics shall assist
Abbott in completing the Project, including but not limited to Seattle Genetics’ responsibility for the following: 
  

	 	a.	Providing Abbott with applicable analytical methods and reference materials qualified to Abbott’s standards (which standards shall reasonably comport with industry standards)
for: (1) raw materials. (2) in-process sample testing and (3) the release of Bulk Drug Substance; 

  

	 	b.	Providing Abbott with technical data on Bulk Drug Substance that includes, but is not limited to, the following: (i) material safety data sheets with environmental and safety
information, and (ii) additional detailed data, if necessary, to define potential hazards and establish employee exposure levels; 

  

	 	c.	Obtaining and providing Abbott with copies of Regulatory Filings as necessary for the pre-approval inspection; and 

  

	 	d.	Maintaining a stability program for, and retaining samples of, the Bulk Drug Substance. 

  
 5. Payment for Abbott’s Development Efforts 
  
 5.1 Research and Development Fee. To reimburse Abbott for its participation in the Project in compliance with the
activities described therein and in this Agreement, and in accordance with the Payment Schedule, Seattle Genetics shall pay Abbott a research and development fee (“Research and Development Fee”), which fee in the aggregate upon
completion of the Project may be [***], but shall not [***], unless revisions occur in the Project scope in accordance with the terms of this Article 5. The maximum [***] of [***] the costs for the services to be performed [***] and the raw
materials, resins, disposable process components, reagents and testing supplies which are currently [***]; provided, however, that if the costs of raw materials, resins, disposable process components, reagents and testing supplies
[***], Seattle Genetics shall[***] for those excess costs and the Research and Development Fee shall be [***] by the [***] of those excess costs. The Parties understand and agree that the Research and Development Fee is comprised of, in part, on a
[***], the [***] described in Section 2.3. The Research and Development Fee shall [***] to Abbott as outlined in the Payment Schedule. Any such modifications agreed upon by the Parties to the scope of the Project shall be incorporated into the
Payment Schedule by a written agreement between Seattle Genetics and Abbott. 
  
 5.2 Changes in Project Scope. If changes occur in the Project or Bulk Drug Substance Specifications, or if technical difficulties require that Abbott perform either additional work or repeat work, and provided
such work is unrelated to Abbott’s fault or negligence, in advance of incorporating such changes or performing any work associated therewith, Abbott shall consult with Seattle Genetics and thereafter provide Seattle Genetics with a new or
revised written test protocol with cost estimates for such work. If Seattle Genetics approves such fee and protocols in writing, Abbott shall perform such 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	9	  	 

 work and Seattle Genetics shall pay Abbott’s fee for such work in the manner and at the time as agreed upon by the
Parties in writing in conjunction with the approval of the work. 
  
 5.3 Additional Filing Costs. Seattle Genetics shall reimburse Abbott for Abbott’s reasonable out of pocket costs paid to any Third Party, which are subject in each case to written pre-approval by Seattle Genetics, associated
with any filings with Regulatory Authorities including but not limited to the filing of a CMC or CMC amendment, in support of Seattle Genetics’ Regulatory Filings with respect to Bulk Drug Substance. Seattle Genetics also shall reimburse Abbott
for those reasonable out of pocket costs paid to any Third Party, which are subject in each case to written pre-approval by Seattle Genetics, for any work requested by Seattle Genetics to produce and assemble documentation for Bulk Drug Substance
registrations outside the United States. Seattle Genetics shall not be obligated to pay or reimburse Abbott any of its costs associated with its establishment license or otherwise relating to its qualification as a manufacturer of biological product
for human use, except in the event that such costs are uniquely attributable to the manufacture of Bulk Drug Substance, in which event, Seattle Genetics shall be responsible for such costs. 
  
 6. Pilot Scale and Clinical Supplies 
  
 6.1 Pilot Scale Supplies. Subject to Section 2.1, as part of the
development portion of the Project, Abbott shall manufacture and provide to Seattle Genetics product that results from up to (as determined by Seattle Genetics) [***] of Bulk Drug Substance. Apart from Section 2.1, and notwithstanding any other
terms or conditions to the contrary contained herein, including, without limitation Section 13.2, Abbott makes no warranties, express or implied, with respect to Bulk Drug Substance produced for pilot scale supplies pursuant to this Section 6.1. All
warranties, express or implied, including without limitation, the implied warranties of merchantability, fitness for a particular purpose and non-infringement, are hereby disclaimed by Abbott with respect to Bulk Drug Substance manufactured pursuant
to this Section 6.1. 
  
 6.2 [***] Clinical Supplies.
Subject to Section 2.1, as part of completing the Project, Abbott shall manufacture and provide to Seattle Genetics in [***] clinical supplies of Bulk Drug Substance supplies that result from [***] according to the mutually agreed final Batch
Records and Bulk Drug Substance Specifications. Abbott warrants the [***] in accordance with Section 13.2. The Parties shall mutually agree on any alteration of the Project Schedule and Bulk Drug Substance amount. 
  
 6.3 Additional Clinical Supplies. If additional [***] clinical supply
is desired by Seattle Genetics, approximately [***] in advance of the desired additional clinical supply Bulk Drug Substance start date, Seattle Genetics shall provide Abbott written notice of the same. The parties shall mutually agree on a date for
supplying the additional clinical Bulk Drug Substance. Based on such mutually agreed upon date Seattle Genetics shall provide Abbott a non-revocable Purchase Order for its requirements of additional clinical Bulk Drug Substance to be supplied by
Abbott. The price of Bulk Drug Substance purchased pursuant to this Section 6.3 shall be [***], excluding raw material costs, per batch, subject to Section 8.2. Abbott warrants the additional [***] in accordance with Section 13.2. 
  
 6.4 Revisions to Project Schedule. No revisions may be made to the
pilot scale and 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	10	  	 

 clinical development schedule portion of the Project Schedule unless mutually agreed upon in writing by Seattle Genetics
and Abbott. The Parties shall mutually agree to the revision in fees associated with such agreed upon adjustment to such schedule. 
  
 7. Manufacture and Commercial Supply of Bulk Drug Substance 
  
 7.1 Purchase and Sale of Commercial Bulk Drug Substance. During the Term, Abbott shall manufacture and deliver commercial Bulk Drug Substance, in
accordance with the terms of this Agreement, for the benefit of Seattle Genetics or its designee. Seattle Genetics shall purchase, in accordance with the terms of this Agreement, its commercial Bulk Drug Substance requirements in the Territory up to
the Maximum Quarterly Capacity from Abbott; provided that Abbott is able to supply commercial Bulk Drug Substance in accordance with Article 9; and provided further that Seattle Genetics shall have the right, in an effort to ensure a secure
commercial supply of Bulk Drug Substance, to enter into a [***] with a company other than Abbott for the supply of up to [***] of Seattle Genetics’, its Affiliates, subsidiaries, licensees, sublicensees and contractors’ worldwide
commercial supply requirements of Bulk Drug Substance (the “[***]”). 
  
 Seattle Genetics hereby agrees that Abbott will qualify as the [***] if Abbott: 
  

	 	(a)	can demonstrate its ability to supply [***] of Seattle Genetics’, its Affiliates, subsidiaries, licensees, sublicensees and contractors’ worldwide commercial supply
requirements of Bulk Drug Substance for a projected period of [***] from a [***] facility more than [***] from the manufacturing site supplying any other portion of Seattle Genetics’ requirements of commercial Bulk Drug Substance; and

  

	 	(b)	demonstrates that additional capacity is available at Abbott’s manufacturing site that is then supplying Bulk Drug Substance for a projected period of at [***]; and

  

	 	(c)	the Parties mutually agree on a revised Bulk Drug Substance price, delivery dates and other applicable terms and conditions acceptable to both parties. 

  

	 	 	Abbott shall manufacture commercial Bulk Drug Substance in accordance with the Bulk Drug Substance Specifications. The Parties may alter from time to time the commercial Bulk Drug
Substance Specifications by mutual written agreement without amending this Agreement in accordance with Section 8.2. In the event that Abbott intends to [***] at any time during the Term, then within [***]. Seattle Genetics shall have the option
exercisable at any time during this Agreement, after the completion of [***], to either (i) terminate this Agreement with prior written notice to Abbott and in accordance with Section 12.2, provided however, that Seattle Genetics its Affiliates,
subsidiaries, licensees, sublicensees and/or contractors, as applicable, [***]; or (ii) terminate this Agreement with prior written notice to Abbott and in accordance with Section 12.2 and [***]. 

  
 7.2 Raw Materials and Components. Abbott shall source all raw
materials and components necessary for the manufacture of the commercial Bulk Drug Substance. Such raw materials and components are included in the commercial price of the commercial Bulk Drug 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	11	  	 

 Substance as detailed in Exhibit D. 
  
 8. Manufacture of Bulk Drug Substance 
  
 8.1 Use of Third Parties. Abbott shall not utilize a Third Party to manufacture any portion of the Bulk Drug Substance without first obtaining
Seattle Genetics’ written consent, which consent shall not be unreasonably withheld, conditioned or delayed. In the event that Abbott is authorized to utilize a Third Party in the manufacture of Bulk Drug Substance, such Third Party shall be
approved by Abbott’s Quality Assurance department. Any such contract entered into by Abbott and a Third Party shall contain provisions substantially similar to those set forth in this Agreement pertaining to the audit of Abbott, that allow
Seattle Genetics to audit such Third Party’s facilities. Abbott agrees that it shall remain liable for the performance of Abbott’s obligations hereunder in the event that Abbott is authorized to use a Third Party to perform certain of
Abbott’s obligations on its behalf. It shall be deemed reasonable for Seattle Genetics to withhold consent to Abbott’s utilization of a Third Party to manufacture any portion of the Bulk Drug Substance in the event that such utilization
would have a substantial likelihood of (a) impairing or jeopardizing any pending or actual regulatory approval for the manufacture of the Bulk Drug Substance, (b) adversely affecting the regulatory status of the Bulk Drug Substance or (c) materially
delaying delivery schedules, increasing the pricing or adversely affecting the quality of the Bulk Drug Substance. 
  
 8.2 Modification of Bulk Drug Substance Specifications. Neither Party shall implement any modification, material or otherwise, to the Bulk Drug
Substance Specifications without the other Party’s prior written approval, provided however that Abbott’s consent shall not be unreasonably withheld. Prior written approval of Seattle Genetics for the purposes of this Section 8.2 shall be
the written approval of Seattle Genetics’ Senior Vice President of Development or Chief Executive Officer. Abbott shall submit to Seattle Genetics a revised price for either the current or future Stage of development during the Project or the
Bulk Drug Substance that reflects such cost increase or decrease resulting from any of the following events: (i) the Bulk Drug Substance Specifications are modified by mutual written agreement, (ii) the Bulk Drug Substance Specifications must be
modified by requirement of any Regulatory Authority, or (iii) a process change is required as part of the CMC or other applicable governmental application, and such modification or process change materially increases or decreases Abbott’s cost
to manufacture Bulk Drug Substance. Abbott and Seattle Genetics shall mutually agree on the cost allocation of such change. In the event the Parties are unable to agree on such cost allocation, Abbott may refuse to implement the change in which
event, Seattle Genetics may terminate this Agreement upon prior written notice and in accordance with Section 12.2 or Abbott may terminate this Agreement upon prior written notice and in accordance with Section 12.3. If such modification results in
the requirement to reprocess and/or retest previously manufactured and otherwise acceptable Bulk Drug Substance, any additional costs incurred by Abbott in such reprocessing and/or retesting shall be paid within the [***] of the mutual written
agreement of the Parties for Abbott to reprocess and/or retest the Bulk Drug Substance; or (ii) [***] after receipt of the final report of the results of the retest or reprocessing. The Parties hereby acknowledge that it is their joint objective to
develop and implement a manufacturing process that is as efficient and cost effective as possible, and to continue to improve its efficiency, as may be permitted by Regulatory Authorities. During the Term, the Parties shall discuss and negotiate in
good faith regarding the impact of 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	12	  	 

 implementation of a scale-up process and/or improved process, which may result in a cost reduction. 
  
 8.3 Modification of Bulk Drug Substance Process. Abbott shall not make
any process changes with respect to the manufacture of the Bulk Drug Substance without prior written approval from Seattle Genetics’ Senior Vice President of Development or Chief Executive Officer. Abbott shall not make any facility changes
with respect to the manufacture of the Bulk Drug Substance without providing Seattle Genetics with prior written notice. Prior to any such change in the manufacturing or facility change being made, Seattle Genetics shall be responsible for obtaining
(a) all necessary approvals from Regulatory Authorities and (b) to the extent necessary and under terms to be agreed upon in writing by Seattle Genetics, and borne by Seattle Genetics exclusive of Abbott, licensure from Abbott or any Third Party in
order to practice such process change for the manufacture of Bulk Drug Substance with respect to such modifications. Modifications to Abbott’s facilities and the cost thereof resulting from a change in law, rule, or regulation shall be the
responsibility of Abbott, except to the extent that such costs are uniquely attributable to the manufacture of Bulk Drug Substance, in which case Seattle Genetics shall be responsible for such costs. Abbott shall be solely responsible for obtaining
any necessary approvals from Regulatory Authorities for facility changes. 
  
 8.4 Bulk Drug Substance Title and Shipment. Any Bulk Drug Substance manufactured by Abbott pursuant to this Agreement shall be shipped [***] using validated shipping methods, which shall be part of the Bulk
Drug Substance Specifications. [***]. Shipment shall be via a carrier designated by Seattle Genetics. Abbott shall not ship any Bulk Drug Substance that does not conform to the Bulk Drug Substance Specifications. Each shipment of Bulk Drug Substance
shall be accompanied by documentation in accordance with Exhibits B (Bulk Drug Substance Specifications) and H (Quality Agreement). 
  
 8.5 Bulk Drug Substance Storage. Seattle Genetics shall pay Abbott for any Bulk Drug Substance storage costs at the Bulk Drug Substance Storage
Rate (excepting retained samples) incurred by Abbott at Seattle Genetics’ request for storage after the period ending [***] after release of post Launch Date Bulk Drug Substance, provided that such Bulk Drug Substance was forecasted by Seattle
Genetics according to Article 9. 
  
 8.6 Quality Control.
Abbott shall apply its quality control procedures and in-plant quality control checks on the manufacture of Bulk Drug Substance for Seattle Genetics in the same manner as Abbott applies such procedures and checks to bulk drug substance of similar
nature manufactured for sale by Abbott, which in all events will at least meet generally accepted standards of quality control in the manufacture of biologics in the pharmaceutical industry. In addition, Abbott will test and release Bulk Drug
Substance to Seattle Genetics in accordance with the Bulk Drug Substance Specifications described in Exhibit B. 
  
 8.7 Quality Assurance. The Parties have approved a quality agreement (“Quality Agreement”) which is attached hereto as Exhibit H,
outlining the responsibilities and key contacts for quality and compliance-related issues. Items contained in the Quality Agreement include, but are not limited to recalls, annual product reviews, returned goods, regulatory audits, compliance with
cGMP and compliance with such other quality related concerns as are deemed appropriate by the Parties. In the event any terms of the Quality Agreement conflict with or are 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	13	  	 

 inconsistent with the terms of this Agreement, the terms of the Quality Agreement shall govern and control with regards
to terms related to quality assurance or control and otherwise the terms of this Agreement shall govern and control. 
  
 8.8 Audits. Seattle Genetics shall have the right, upon [***] prior written notice to Abbott and receipt of Abbott’s consent thereto, which
consent shall not be unreasonably withheld, conditioned or delayed, to conduct during normal business hours a quality assurance audit and inspection of Abbott’s records and Bulk Drug Substance facilities relating to the manufacture of Bulk Drug
Substance and to perform follow-up audits as reasonably necessary. Prior to Abbott commencing the production of the first batch of commercial Bulk Drug Substance as ordered by Seattle Genetics, such audits and inspections may be conducted from time
to time on a reasonable basis. Once Abbott has commenced production of the first batch of commercial Bulk Drug Substance, such audits may only be conducted [***] each calendar year. The duration of such audits shall not exceed [***] and such audits
shall be performed by no more than [***], unless Seattle Genetics reasonably believes that a longer audit or additional personnel are necessary and provides its reasonably adequate reasons for such belief to Abbott in writing. If Seattle Genetics
wishes to perform audits more often than [***] per calendar year or over a period in excess of [***], Seattle Genetics shall pay Abbott [***] per additional audit day. Notwithstanding the foregoing, in the event that an audit is required by Seattle
Genetics due to quality issues that arise, per the terms of Sections 8.9 and/or 9.8, Seattle Genetics shall be entitled to conduct one additional audit for each such occurrence [***]. If more than [***] perform the audit, Seattle Genetics shall pay
Abbott [***]. In addition, Seattle Genetics or its licensees shall have the right at any time during the Term, upon [***] prior written notice to Abbott, to conduct any audits specifically mandated by any Regulatory Authority or to respond to
specific questions from any such Regulatory Authority. Notwithstanding anything to the contrary contained in this Agreement, any audits conducted on Abbott’s property shall be subject to Abbott’s rules and regulations regarding, without
limitation, security and confidentiality and shall be conducted in the presence of Abbott’s employees. In addition, Abbott shall promptly provide Seattle Genetics a written response to any such audit report received by Abbott. 
  
 Visits by Seattle Genetics to Abbott’s Bulk Drug Substance facilities
may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 11 hereof. The results of such audits and inspections shall be considered Confidential Information under Article 11
and shall not be disclosed to Third Parties, including but not limited to any Regulatory Authority, unless required by law and upon prior written notice to Abbott. If Seattle Genetics utilizes auditors that are not employees of Seattle Genetics,
each of such auditors shall execute a non-disclosure agreement with confidentiality terms at least as stringent as those set forth in Article 11. 
  
 Abbott shall be responsible for inspections of its manufacturing facilities by any Regulatory Authorities and shall promptly notify Seattle Genetics if
such inspections are directly related to the manufacture of Seattle Genetics’ Bulk Drug Substance or if the results of a non-related inspection could materially impair Abbott’s ability to perform in accordance with this Agreement. With
respect to inspections related to the manufacture of Bulk Drug Substance, Abbott shall (a) provide Seattle Genetics with copies of all documents, reports or communications received from or given to any Regulatory Authority associated therewith, (b)
permit Seattle Genetics’ representatives to be present on site at such inspections, and to 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	14	  	 

 participate, at Abbott’s reasonable discretion, as appropriate, based on questions or requests specific to Seattle
Genetics and as permitted by Regulatory Authorities, in such inspections, and (c) allow Seattle Genetics to provide comments to Abbott, and Abbott shall draft any such correspondence to Regulatory Authorities in connection therewith. 
  
 Seattle Genetics shall promptly notify Abbott regarding any inspection on
Seattle Genetics property related to the manufacture of Bulk Drug Substance. 
  
 8.9 Recalls. Product recalls and contacts with any Regulatory Authorities relating to the recall of Product shall be the responsibility and under the control of Seattle Genetics. In the event that Abbott has
reason to believe that any Products should be recalled or withdrawn from distribution, it shall promptly inform Seattle Genetics in writing of such belief. Seattle Genetics shall notify the appropriate Regulatory Authorities of any recall and shall
be responsible for coordinating all necessary activities regarding the action taken. Abbott and Seattle Genetics shall fully cooperate to complete the recall, and shall thereafter resolve any allocation of liability as may be appropriate in
accordance with the terms of this Agreement. The costs and expenses of conducting any recall shall be treated as follows: 
  

	 	(a)	If any Product is recalled as a result of the supply by Abbott of Bulk Drug Substance that was not manufactured in compliance with the terms of this Agreement, then Abbott shall
reimburse Seattle Genetics for all reasonable expenses actually incurred as a result of such recall including the cost of the Bulk Drug Substance. If Seattle Genetics elects to utilize a Third Party to conduct a recall, Seattle Genetics shall notify
Abbott of the identity of such Third Party; 

  

	 	(b)	If each Party contributes to the cause for a recall, the expenses actually incurred as a result of such recall will be shared in proportion to each Party’s responsibility; and

  

	 	(c)	All recalls of Product other than those described in clauses (a) or (b) shall be at Seattle Genetics’ sole expense. Seattle Genetics shall give Abbott prompt written notice of
any Product recalls that Seattle Genetics believes were caused or may have been caused by Abbott’s failure to comply with this Agreement. 

  
 8.10 Payment Terms 
  
 (a) Price and Payment. For (a) work performed in conducting the Project in accordance with this Agreement, (b) Deliverables to Seattle Genetics as
specified in Exhibit C, and (c) Bulk Drug Substance that is manufactured and delivered in accordance with this Agreement and meets the Bulk Drug Substance Specifications, Abbott shall invoice Seattle Genetics according to the Payment Schedule and
Bulk Drug Pricing in Exhibit D. Seattle Genetics shall make payment of all undisputed amounts due under this Agreement net [***] from the date of receipt of Abbott’s invoice; provided that with respect to payments owed by Seattle Genetics for
[***] pursuant to Section 2.3, payment terms shall be net [***] from the date of receipt of Abbott’s invoice. All payments due under this Agreement shall be paid in U.S. Dollars by wire transfer (Seattle Genetics will endeavor but is not
obligated to provide twenty four (24) hours advance notice of each wire transfer to the bank account identified below or such other 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	15	  	 

 bank accounts as Abbott shall designate in writing to Seattle Genetics) or by such other means agreed to by the Parties,
for value, in each case at the expense of the Seattle Genetics: 
  
 [***] 
  
 (b) Taxes. Any federal, state, county or
municipal sales or use tax, excise, customs charges, duties or similar charge, or any other tax assessment (other than that assessed against income, real property, or the right of Abbott to do business), license, fee or other charge lawfully
assessed or charged on the manufacture, sale or transportation of Bulk Drug Substance sold pursuant to this Agreement shall be paid by and the responsibility of Seattle Genetics. 
  
 8.11 Dedicated Equipment. Seattle Genetics shall pay the cost of additional equipment purchased by Abbott
(“Dedicated Equipment”), which is required for Abbott to manufacture Bulk Drug Substance for Seattle Genetics (subject to the approval conditions stated below). Abbott shall advise Seattle Genetics of any Dedicated Equipment
required and the estimated costs associated with the purchase, installation and validation of such Dedicated Equipment. Abbott must receive written approval (letter, e-mail or facsimile) by an authorized Seattle Genetics representative prior to the
purchase of any such Dedicated Equipment. Such Dedicated Equipment shall be used exclusively for manufacturing of Bulk Drug Substance hereunder, unless otherwise permitted in advance by Seattle Genetics in writing. [***]. Abbott shall bill Seattle
Genetics for the reasonable installation and equipment validation costs after Abbott installs the Dedicated Equipment. Seattle Genetics shall be responsible for any licensing fees, milestones, or royalties associated with Dedicated Equipment. This
Section 8.11 shall not apply to any replacement equipment purchased by Abbott because of obsolescence (technical or otherwise). Dedicated Equipment, as estimated on or around the Effective Date, is outlined in Exhibit F. Abbott shall own any
Dedicated Equipment. In the event this Agreement is terminated, Abbott and Seattle Genetics shall in good faith agree on the commercially reasonable procedures and costs related to the transfer of title to and possession of Dedicated Equipment to
Seattle Genetics. Seattle Genetics agrees and acknowledges that upon termination of this Agreement, unless otherwise agreed in accordance with this Section, Seattle Genetics shall own such Dedicated Equipment and shall remove its Dedicated Equipment
from Abbott’s property within thirty (30) days after the termination of the Agreement. Upon such termination, if Abbott wishes to retain any such Dedicated Equipment (in Abbott’s sole discretion), and Seattle Genetics approves of such
retention in writing, Abbott shall [***]. In addition to Exhibit F, Abbott shall submit quarterly to Seattle Genetics, an updated estimate of Dedicated Equipment costs for the entire Project. 
  
 Risk of loss of all Dedicated Equipment shall be retained by Seattle
Genetics; provided, however, that Abbott shall be responsible for replacing any Dedicated Equipment that is destroyed due to Abbott’s negligence, willful misconduct, unauthorized use or unauthorized use with other products. All Dedicated
Equipment shall remain at Abbott’s manufacturing facilities. 
  
 Abbott shall be responsible for maintaining and servicing the Dedicated Equipment. Seattle Genetics, however, shall be responsible for the cost of non-routine maintenance and servicing of the Dedicated Equipment (such as major repairs and
material parts replacement), except to the extent caused by Abbott’s negligence, willful misconduct, 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	16	  	 

 unauthorized use or use with other products in which case Abbott shall be responsible. Abbott shall notify Seattle
Genetics prior to the performance of any non-routine maintenance or servicing, and Seattle Genetics shall reimburse Abbott at cost for such maintenance or servicing costs that Seattle Genetics has authorized to be incurred and for which it is
responsible. 
  
 9. Orders and Forecasts for Commercial Supply
of Bulk Drug Substance 
  
 9.1 First Year Estimate.
Seattle Genetics shall, within [***] after filing its BLA for Bulk Drug Substance, provide Abbott with a written estimate of Seattle Genetics’ monthly requirements of commercial Bulk Drug Substance to be supplied by Abbott for the first
Contract Year; provided, however, the Parties acknowledge that most if not all requirements of commercial Bulk Drug Substance for the first Contract Year may be obtained through the [***] described in [***] of the [***]. Abbott acknowledges that
such quantities are estimates only and are nonbinding. 
  
 9.2
First Order. Abbott and Seattle Genetics shall cooperate fully in estimating and scheduling production for Seattle Genetics’ first commercial order of Bulk Drug Substance in anticipation of regulatory approval of Bulk Drug Substance.

  
 9.3 First Firm Order. At least [***] in advance (the
“Initial Order Date”) of the desired commercial Bulk Drug Substance start date for manufacturing, Seattle Genetics shall place its first firm Purchase Order for [***] following the desired Bulk Drug Substance availability date to be
mutually agreed to. At the same time, Seattle Genetics shall provide to Abbott Seattle Genetics’ estimate of its monthly requirements of commercial Bulk Drug Substance to be supplied by Abbott for the next succeeding [***] period. For
illustrative purposes only, the following are examples of how the Parties intend to apply this Section 9.3: 
  
 Example: If the desired Bulk Drug Substance start date for manufacturing is [***], Seattle Genetics will place its first firm Purchase Order on the
Initial Order Date (which will be [***]) for its expected orders to be delivered during the [***] following the desired Bulk Drug Substance availability date. 
  

9.4 Rolling Forecast. At the beginning of each Calendar Quarter following the Initial Order Date, Seattle Genetics shall provide to Abbott a
rolling [***] projection of requirements of commercial Bulk Drug Substance to be supplied by Abbott, with the first [***] of such projection consisting of firm Purchase Orders (subject to Section 9.3) and the remaining [***] of such projection
consisting of Seattle Genetics’ best estimate forecast of its commercial Bulk Drug Substance requirements (the “Rolling Forecast”). For illustrative purposes only, the following are examples of how the Parties intend to apply
this Section 9.4: 
  
 Example: Considering the scenario
under Example 1 of Section 9.3, at the beginning of each Calendar Quarter following the Initial Order Date, commencing the [***], Seattle Genetics shall provide to Abbott a rolling [***] forecast in the format described above; provided, however, the
Parties recognize that all months under the first firm Purchase Order will remain firm due to the initial firm forecast produced under Section 9.3. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	17	  	 

 9.5 Purchase Order Acceptance. If a firm Purchase Order is not in excess of one [***] of the
amounts previously reflected for the applicable months in the immediately preceding Rolling Forecast, and the amounts in the firm Purchase Order are in compliance with the [***], the firm Purchase Order shall be deemed accepted by Abbott upon its
receipt thereof. If, however, the firm Purchase Order exceeds such [***], or the amounts ordered for any given Calendar Quarter would exceed the [***], then, within thirty (30) days after receipt of Seattle Genetics’ firm Purchase Orders for
commercial Bulk Drug Substance, Abbott shall confirm to Seattle Genetics its acceptance or non acceptance of the Purchase Order, the delivery date and the quantity of commercial Bulk Drug Substance ordered by Seattle Genetics, however, the Parties
acknowledge that a firm Purchase Order may be in excess of [***] or exceed the Calendar Quarter [***] during the [***] time period immediately preceding the anticipated First Commercial Sale. During such time period, Abbott shall use commercially
reasonable efforts to accept the firm Purchase Order in excess of one [***] or the Calendar Quarter [***]. In the event that Abbott is unable to meet Seattle Genetics’ order, then Seattle Genetics may either (a) reduce its firm Purchase Order
to no more than [***] of the amounts previously reflected for the applicable months in the Rolling Forecast and to fall into compliance with the [***] or (b) employ a Third Party supplier of commercial Bulk Drug Substance, provided that the Third
Party supplier is only employed to supply the firm Purchase Order for which Abbott was unable to fulfill. 
  
 9.6 Firm Order Changes. If, due to significant unforeseen circumstances, Seattle Genetics requests to increase Seattle Genetics’ firm Purchase
Order within the [***] firm Purchase Order timeframe, then Abbott shall attempt to accommodate the changes within reasonable manufacturing capabilities and efficiencies. Abbott shall advise Seattle Genetics in writing of the costs associated with
making any such change and Seattle Genetics shall be deemed to have accepted the obligation to pay Abbott for such costs if Seattle Genetics indicates to Abbott, in writing, that Abbott should proceed to make the change. Abbott is obligated to fill
all accepted firm Purchase Orders for commercial Bulk Drug Substance provided that (i) the Purchase Order is no greater than [***] of the amounts previously reflected for the applicable months in the immediately preceding Rolling Forecast and (ii)
the firm Purchase Order is in compliance with the [***]. Abbott shall use reasonable commercial efforts to fill any accepted firm Purchase Orders for commercial Bulk Drug Substance in excess of such [***]. 
  
 9.7 Purchase Order Terms. Each Purchase Order or any acknowledgment
thereof, whether printed, stamped, typed, or written shall be governed by the terms of this Agreement and none of the provisions of such Purchase Order or acknowledgment shall be applicable except those specifying Bulk Drug Substance and quantity
ordered, delivery dates, special shipping instructions and invoice information. 
  
 9.8 Acceptance of Bulk Drug Substance. 
  
 (a) Acceptance. Seattle Genetics shall inspect the Bulk Drug Substance manufactured by Abbott following receipt thereof and, within [***] following receipt of the items to be delivered pursuant to Section 8.4,
(i) shall give Abbott written notice (a “Deficiency Notice”) of any Bulk Drug Substance that fails to comply with any of Abbott’s warranties stated in Section 13.2; and (ii) shall reconcile the shipment against the relevant
firm Purchase Order and give Abbott notice of any shortages. Should Seattle Genetics fail to provide Abbott with written notice of its acceptance or rejection of the Bulk Drug Substance within the above described [***] 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	18	  	 

 period, then the delivery shall be deemed to have been accepted by Seattle Genetics on the [***] after delivery of the
items required pursuant to Section 8.4, except with respect to defects or items of nonconformance which could not be discovered at such time in the exercise of reasonable care, provided that in regard to any such non-discoverable defects, Seattle
Genetics shall notify Abbott of such defects prior to [***] after acceptance of such Bulk Drug Substance in accordance with this Section 9.8(a). In the event that Seattle Genetics does not provide notice regarding non-discoverable defects within
such [***] time period, then Seattle Genetics shall be deemed to have accepted such Bulk Drug Substance. Any written notice to Abbott of its failure to deliver an item required to be delivered pursuant to Section 8.4 or of a shortage of greater than
[***] of Bulk Drug Substance, as required to be delivered by Abbott in accordance with Section 9.5 shall be deemed to be a Deficiency Notice. 
  
 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice pertaining to compliance with the Bulk Drug Substance Specifications, Abbott
shall have [***] to advise Seattle Genetics in writing that it agrees or disagrees in good faith with the contents of such Deficiency Notice (the “Response Notice”). If Seattle Genetics and Abbott fail to agree within [***] after
Seattle Genetics’ receipt of Abbott’s Response Notice, then the Parties shall promptly mutually select an independent laboratory to evaluate (using the test methods described in the Bulk Drug Substance Specifications) if the Bulk Drug
Substance deviates from any Bulk Drug Substance Specifications. Such evaluation shall be binding on the Parties, and if such evaluation certifies that the Bulk Drug Substance deviates from any Bulk Drug Substance Specifications, Seattle Genetics may
reject that Bulk Drug Substance in accordance with Section 9.8(c). If such evaluation reveals that the Bulk Drug Substance in question complies with the Bulk Drug Substance Specifications and Abbott has complied with all the warranties in Section
13.2, then Seattle Genetics shall be deemed to have accepted delivery of such Bulk Drug Substance upon the independent laboratory issuing its opinion. If the Bulk Drug Substance is found to be in compliance with the Bulk Drug Substance
Specifications, Seattle Genetics shall pay the costs of the independent laboratory. Otherwise, Abbott shall pay such costs. 
  
 (c) Rejection. Subject to the provisions of Section 9.8(b), Seattle Genetics has the right to reject and return, at the expense of Abbott, any
portion of any shipment of Bulk Drug Substance that deviates from any Bulk Drug Substance Specifications, without invalidating any remainder of such shipment, to the extent that such deviation arises from Abbott’s failure to manufacture and
supply the Bulk Drug Substance in accordance with this Agreement (including, without limitation, the Bulk Drug Substance Specifications). In such event, Abbott [***] shall promptly replace such rejected amounts with Bulk Drug Substance that conforms
with the Bulk Drug Substance Specifications; provided, however, that solely with respect to the Bulk Drug Substance supplied as a result of the first [***] manufactured by Abbott pursuant to Section 6.2, Abbott shall only replace such
rejected amounts of Bulk Drug Substance [***] if such failure to conform with Bulk Drug Substance Specifications arises from Abbott’s negligence or willful misconduct, contamination or mechanical failure or any other failure attributable to
Abbott; otherwise, Abbott’s obligation to replace such rejected amounts of Bulk Drug Substance from the [***] shall be contingent on Seattle Genetics paying Abbott [***], in which case Abbott shall conduct an additional [***] and provide all of
the resulting Bulk Drug Substance to Seattle Genetics pursuant to the same terms and conditions as specified in this Agreement pertaining to the [***]. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	19	  	 

 10. Proprietary Ownership of Development Work, Preexisting Technology and License Grants 
  
 10.1 Existing Proprietary Information. Except as otherwise expressly
provided herein, neither Party shall be deemed to have been granted any license or other rights to patent rights, know-how relating to compounds, formulations, or processes which are owned or controlled by the other Party existing as of the
Effective Date. 
  
 10.2 Abbott Inventions. Abbott shall
own all proprietary rights to Abbott Inventions, and may obtain patent, copyright, and/or other proprietary protection relating thereto. Abbott hereby grants to Seattle Genetics an [***] license to each Abbott Invention, which has been incorporated
into the manufacturing process of the Bulk Drug Substance solely for making Bulk Drug Substance. Seattle Genetics shall have the right to [***] the aforementioned license to third parties for the sole purpose of manufacturing Bulk Drug Substance and
provided Seattle Genetics provides Abbott written notice of such [***] and the name of the [***]. Use of such license shall [***], but only in the event that Abbott Patent Rights essential for the manufacture of Bulk Drug Substance are included in
such license. The obligation to [***] shall expire upon the later of (i) the last to expire issued claim contained with such licensed Abbott Patent Rights or (ii) [***]. Prior to incorporating any Abbott Invention into the manufacturing process for
the Bulk Drug Substance that will require [***] in the future, Abbott shall (1) provide Seattle Genetics with all reasonably necessary information regarding the Abbott Invention (provided that such information is within Abbott’s control and
such disclosure is not prohibited or restricted by confidentiality protections, in which event, Abbott shall use reasonable efforts to obtain appropriate waivers to permit disclosure of such information) to allow Seattle Genetics to conduct
intellectual property due diligence, including without limitation all relevant patents, patent applications, and any applicable license agreements (which license agreements are subject to third party confidentiality obligations and may be redacted)
and (2) obtain Seattle Genetics prior written approval for inclusion of such Abbott Invention. In the event that either (x) Abbott incorporates such Abbott Invention without Seattle Genetics’ prior written approval or (y) Seattle Genetics
requires such license because Abbott cannot supply Bulk Drug substance in accordance with the requirements of the Agreement and such failure is not the result of Seattle Genetics actions or negligence, then during such period of time when Abbott
fails to supply Seattle Genetics or until Abbott receives Seattle Genetics’ approval for incorporation of an Abbott Invention, Seattle Genetics shall have a [***] in accordance with this Section 10.2. [***]. In the event that Abbot files a
patent application on an Abbott Invention that has been incorporated into the manufacturing process for the Bulk Drug Substance, then Abbott shall so notify Seattle Genetics within thirty (30) days of the filing of such patent application. Failure
to notify Seattle Genetics of the filing of said patent application on an Abbott Invention shall not excuse Seattle Genetics from [***] on such Abbott Invention if Seattle Genetics has given its prior written approval for inclusion of such Abbott
Invention as set forth above. 
  
 10.3 Seattle Genetics
Inventions. With respect to any ideas, innovations or inventions (whether or not patentable) developed by Seattle Genetics (alone, or in conjunction with Third Parties and exclusive of Abbott) during the Term and relating to the Bulk Drug
Substance, other than Abbott Inventions (“Seattle Genetics Inventions”), Seattle Genetics shall own all proprietary rights to such Seattle Genetics Inventions, and may obtain patent, copyright, and/or other proprietary protection
relating to such ideas, innovations and inventions. During the Term, 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	20	  	 

 Seattle Genetics hereby grants to Abbott a royalty-free, worldwide, nonexclusive license (with the right to grant
sublicenses only upon Seattle Genetics prior written approval in each case) for the sole purpose of satisfying Abbott’s obligations hereunder, to Seattle Genetics Confidential Information, Seattle Genetics Know-How, Seattle Genetics Patent
Rights, Seattle Genetics Inventions and other proprietary rights reasonably necessary to conduct the research and development work described in Articles 3 and 4 hereof, and to comply with Abbott’s obligations hereunder, including without
limitation, making and supplying to Seattle Genetics Bulk Drug Substance hereunder. 
  
 10.4 Joint Inventions. Except for inventions to be owned individually by a Party as described in Sections 10.2 and 10.3 above, each Party shall own a fifty percent (50%) undivided interest in all such
inventions, discoveries and know-how made, conceived, reduced to practice and/or otherwise generated jointly by at least one employee, agent, or other person acting for each Party in the course of this Agreement. The Parties shall choose an external
counsel by mutual agreement to prepare and prosecute any patent applications, U.S. and foreign, covering Joint Inventions. The Parties shall share the expenses associated with the prosecution and maintenance of patent applications and patents
covering joint Inventions. Notwithstanding anything to the contrary in this Agreement, any ideas, innovations or inventions related [***] 
  
 10.5 Payments due to Third Parties. Subject to Sections 8.3 and 14.2(ii), Seattle Genetics shall be [***] that are associated with Third Party
technology used in the making, having made, using, offering for sale, selling, importing and exporting of Product. In the event that Abbott has a license to any Third Party technology related to Abbott’s Manufacture of the Bulk Drug Substance
and to which Abbott has the [***] to Seattle Genetics, the value of such Third Party license is readily ascertainable, and Abbott can obtain an [***] to such Third Party license, Abbott agrees to provide Seattle Genetics with the right to obtain
such a [***] under the Third Party license. 
  
 10.6 [***].
Notwithstanding anything to the contrary in this Agreement, prior to making any Bulk Drug Substance pursuant to Section 7 (Manufacture and Commercial Supply of Bulk Drug Substance) but after [***] is completed, Seattle Genetics shall determine [***]

  

					
	 CONFIDENTIAL AGREEMENT
	  	21	  	 

 11. Confidential Information 
  
 Neither Party shall use or disclose any of the other Party’s Confidential Information received by it without the prior
written consent of the other Party. Except as provided in the following sentence, nothing contained in this Article shall be construed to restrict the Parties from disclosing Confidential Information as is reasonably necessary to perform acts
expressly permitted by this Agreement or such acts the Parties’ could reasonably expect to be performed in conjunction with the approval and/or manufacture of Bulk Drug Substance and/or any Product. However, if either Party is required or feels
it necessary to disclose any of the other Party’s Confidential Information received by it pursuant to this Agreement (whether by audit or otherwise) to any Third Party or governmental authority or agency in compliance with any federal, state
and/or local laws and/or regulations, or pursuant to an order of a court of competent jurisdiction, the disclosing Party shall first notify the Party owning such Confidential Information, prior to any such disclosure, in order to afford the
disclosing Party a reasonable opportunity to obtain a protective order as to such information and will use reasonable efforts to obtain reliable assurance that the information disclosed will be treated confidentially. In any event, each Party shall
make any disclosures of the other Party ‘s Confidential Information received by it pursuant to this Agreement only to the extent required, and only to such persons who have a need to know. The obligations of each Party relating to the other
Party’s Confidential Information shall expire [***] after termination of this Agreement. The disclosure of Confidential Information shall not constitute the grant of any license or any other rights, or generate any business arrangements, unless
specifically set forth herein or in another writing. 
  
 Neither
Party shall disclose the existence or any terms and conditions of this Agreement except (a) with the other Party’s prior written consent or (b) as required to comply with foreign, federal, state or local laws and regulations (including, without
limitation, federal and state securities laws and regulations). 
  
 Each Party acknowledges that the remedy at law for any breach of this Article 11 would be inadequate, and the full amount of damages that may result from such breach is not readily susceptible to being measured in monetary terms.
Accordingly, in the event of a breach or threatened breach by either Party of this Article 11, the other Party shall be entitled to immediate injunctive relief prohibiting any such breach and requiring the immediate return of all Confidential
Information. Such remedies shall be in addition to any other remedies that may be available. 
  
 12. Term and Termination 
  
 12.1 Term. This Agreement shall become effective as of the Effective Date, and unless sooner terminated hereunder, shall continue in effect until the completion of the [***] Contract Year following the Launch Date (the
“Initial Term”). AT THE END OF THE INITIAL TERM, THE INITIAL TERM SHALL BE AUTOMATICALLY EXTENDED AND, UNLESS SOONER TERMINATED HEREUNDER, SHALL TERMINATE ONLY AFTER NO LESS THAN [***] PRIOR WRITTEN NOTICE OF A PARTY’S INTENT
TO TERMINATE IS GIVEN TO THE OTHER PARTY (WHICH NOTICE MAY BE GIVEN PRIOR TO OR AFTER THE EXPIRATION OF THE INITIAL TERM) (“Term”). 
  
 12.2 Seattle Genetics Termination Rights. Seattle Genetics may terminate this Agreement (i) upon [***] prior written notice to Abbott if Seattle
Genetics determines in good 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	22	  	 

 faith that the clinical, development and/or commercial stage of the Bulk Drug Substance, before or after the Launch Date,
is not technically, clinically or commercially feasible as determined by Seattle Genetics, subject to Section 7.1 and this paragraph, (ii) upon [***] prior written notice to Abbott, in the event Seattle Genetics delivers to Abbott [***] or more
Deficiency Notices in any [***] period or Deficiency Notices in respect of [***] consecutive shipments, (iii) immediately after prior written notice to Abbott in accordance with Section 2.2 or (iv) in accordance with Sections 7.1 or 8.2 after prior
written notice in accordance with such Sections. In the event that Seattle Genetics, its Affiliates or its Third Party licensees begins commercial development and sale of the Bulk Drug Substance within [***] of termination of this Agreement in
accordance with clause (i) of this Section, then Abbott shall have the option of reinstating this Agreement and Seattle Genetics shall be obligated to purchase the Bulk Drug Substance from Abbott, provided that Seattle Genetics’ prior
termination of this Agreement was not related to any deficiency uniquely related to Abbott’s facility or performance, including without limitation problems with process development, scale-up, Bulk Drug Substance quality, regulatory issues or
timing delays. 
  
 12.3 Abbott Termination Rights. Abbott
may terminate this Agreement (i) upon [***] prior written notice to Seattle Genetics if Abbott determines in good faith that the development of a commercially reasonable manufacturing process for the Bulk Drug Substance is [***] feasible in [***] or
(ii) immediately after prior written notice to Seattle Genetics in accordance with Sections 2.2 and 8.2. 
  
 12.4 General Termination Rights. Upon the occurrence of the following events, either Party may terminate this Agreement by giving the other Party
[***] prior written notice: 
  

	 	(a)	Upon the bankruptcy or insolvency of the other Party; 

  

	 	(b)	Upon the material breach of any provision of this Agreement by the other Party if the breach is not remedied prior to the expiration of such [***]] notice period, or if the breach
is of a type that cannot be remedied within [***], then a remedy promptly commenced and diligently pursued until complete remediation; or 

  

	 	(c)	Upon the breach of the representations and warranties contained in Section 28. 

  

12.5 Termination in Event of Hardship. In the event that during the Term the general situation and/or the data and/or economic appropriateness
on which this Agreement is based are substantially changed such that it is not commercially reasonable for a Party to proceed towards commercialization of the Bulk Drug Substance, such Party may, after good faith negotiations between the Parties,
terminate this Agreement with [***] prior written notice to the other Party; provided, however, that in the event that Seattle Genetics, its Affiliates or its Third Party licensees subsequently proceeds toward the commercialization of Bulk Drug
Substance, within [***] of termination of this Agreement in accordance with this Section, then Abbott shall have the option of reinstating this Agreement and Seattle Genetics shall be obligated to purchase the Bulk Drug Substance from Abbott,
provided that Seattle Genetics’ prior termination of this Agreement was not related to any deficiency uniquely related to Abbott’s facility or performance, including without limitation problems with process development, scale-up, Bulk Drug
Substance quality, regulatory issues or timing delays. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	23	  	 

 12.6 Termination Due to Regulatory Action. Seattle Genetics may terminate this Agreement upon
[***] written notice in the event that a Regulatory Authority takes any action, lasting more than [***], directly affecting Abbott’s ability to operate its biologics manufacturing business or the manufacturing facilities at which the Bulk Drug
Substance is being made. Abbott shall take reasonable steps to achieve the orderly transition of the manufacturing process to a Third Party and shall pay all costs payable to said Third Party (other than Affiliates of either Party) (less any costs
recoverable by Seattle Genetics in the form of Bulk Drug Substance that may be incorporated into marketable Product) to complete a BLA with respect to the replacement manufacturer’s production of the Bulk Drug Substance provided that
Abbott’s share of such costs shall not exceed [***]. Seattle Genetics shall ensure that the Third Party manufacturer shall be subject to terms of confidentiality with respect to Abbott’s Confidential Information, as well as this Section
12.6, that are no less protective than the confidentiality set forth in Article 11 of this Agreement. 
  
 12.7 Actions on Termination. Upon expiration or termination of this Agreement for any reason, the following shall occur: 
  

	 	(a)	Dedicated Equipment. In accordance with Section 8.11, upon Seattle Genetics’ option (i) Abbott shall deliver to Seattle Genetics (at Seattle Genetics’ cost of
removal and shipment) all Dedicated Equipment, or if the Parties mutually agree (ii) Abbott shall purchase all Dedicated Equipment from Seattle Genetics at its depreciated (calculated on a straight-line basis) book value thereof;

  

	 	(b)	Confidential Information and Records. Subject to Section 12.7(c), each Party shall deliver to the other, or destroy at the Parties election, all materials, reports, and other
documents (including copies thereof except that either Party may keep one copy of Confidential Information for its archival purposes subject to the confidentiality provisions in this Agreement) in its possession or control containing Confidential
Information of the other Party, and each will cease to make use of the other’s Confidential Information; in particular, the Bulk Drug Substance Specifications shall be promptly returned to Seattle Genetics along with the following records,
which are to be maintained by Abbott on behalf of Seattle Genetics during the Term: Bulk Drug Substance Specific Master Manufacturing Batch Records; Drug Product Specific Test Methods; Drug Product Specific Standard Operating Procedures; Drug
Product Specific Material Specifications (in-process limits and Drug Product specifications); and Drug Product Specific Validation Protocols and Reports (Equipment, Process, Cleaning, Test Method); 

  

	 	(c)	Technology Transfer. Upon Seattle Genetics’ request and provided that the Agreement neither (i) was terminated by Abbott in accordance with Section 12.4 nor (ii) has
expired or terminated in accordance with Section 12.1, Abbott will reasonably assist Seattle Genetics with the transfer of the manufacturing process associated with the Bulk Drug Substance to Seattle Genetics or its designee (in the event that the
Agreement was terminated by Abbott in accordance with Section 12.4 or has expired or terminated in accordance with Section 12.1, Seattle Genetics shall have the option to have Abbott reasonably assist Seattle Genetics with the transfer of the
manufacturing process associated with the Bulk Drug Substance to Seattle Genetics or its designee, at Seattle Genetics sole cost and expense); 

  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	24	  	 

	 	(d)	Raw Materials. Abbott shall return to Seattle Genetics all unused raw materials associated with Bulk Drug Substance to the extent such raw materials have been paid for by
Seattle Genetics; 

  

	 	(e)	Maintenance of Information. Abbott and Seattle Genetics shall continue to maintain information about the Bulk Drug Substance and its production for such time and in such
manner as required by the Regulatory Authorities and shall continue to respond in a timely manner to all queries and requests for information from Regulatory Authorities; and 

  

	 	(f)	Project Reassignment Costs. If the Project is terminated, Abbott shall advise Seattle Genetics of Abbott’s reasonable research and development fees on the Project
incurred in accordance with the Project budget as described in Article 5 of this Agreement (“Incurred Fees”) prior to such termination. The Parties shall negotiate in good faith an appropriate and reasonable adjustment based upon
Abbott’s Incurred Fees and Seattle Genetics’ Research and Development Fee payments previously made following such termination. Unless the Agreement was terminated in accordance with Section 12.4(b) due to Abbott’s material breach,
Seattle Genetics shall pay Abbott for [***] associated with reassignment of resources as determined in good faith by Abbott (“[***]”). Such [***] shall include but not be limited to: [***] (less any avoidable out-of-pocket costs). Abbott
shall use reasonable efforts to minimize [***]. Any such [***] shall be limited to costs incurred within the period of time that is the shorter of (a) actual reassignment of the labor, assets and other resources or (b) the [***] period following the
termination of the Agreement, except to the extent that Seattle Genetics approves such additional costs in writing. Abbott shall provide to Seattle Genetics a detailed summary of Incurred Fees and [***] payable pursuant to this Section 12.7.

  
 12.8 Purchase of Firm Orders. Upon
termination of this Agreement by Seattle Genetics for any reason, except for Abbott’s material breach in accordance with Section 12.4(b), Seattle Genetics shall pay an amount to Abbott equal to the [***]. Notwithstanding the foregoing, if
Abbott is able to resell its unused capacity that was attributable to the firm Purchase Order, it shall provide Seattle Genetics with a reasonable credit, offset or refund (as elected by Seattle Genetics) in an amount to be determined in good faith
by Abbott. Seattle Genetics shall have no purchase obligations beyond the amounts reflected in the firm Purchase Order. 
  
 12.9 Survival Provisions. Termination, expiration, cancellation or abandonment of this Agreement through any means and for any reason shall not
relieve the Parties of any obligation accruing prior thereto, including, but not limited to, the obligation to pay money, and shall be without prejudice to the rights and remedies of either Party with respect to the antecedent breach of any of the
provisions of this Agreement. Further, Articles 1, 10-16, 18-22, 24, 27, and 28 and Sections 2.3 (Payment for [***]), 5.1, 5.3, 8.9, 8.11, 9.3 and 9.4 (firm orders), shall survive the termination of this Agreement. 
  
 13. Warranties; Limitation of Liability. 
  
 13.1 Seattle Genetics Warranties. Seattle Genetics warrants that it
owns or controls all of the rights in and to the Seattle Genetics Patent Rights, Seattle Genetics Know-How, and Confidential Information provided by Seattle Genetics to Abbott hereunder, and that it has the full right and authority to grant to
Abbott the licenses described in Section 10.3. SEATTLE 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	25	  	 

 GENETICS MAKES NO OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO BULK DRUG SUBSTANCE, SEATTLE GENETICS PATENT
RIGHTS, SEATTLE GENETICS KNOW-HOW, AND SEATTLE GENETICS CONFIDENTIAL INFORMATION PROVIDED HEREUNDER. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE
AND NONINFRINGEMENT, ARE HEREBY DISCLAIMED BY SEATTLE GENETICS. IN NO EVENT, EXCEPT PURSUANT TO SECTION 14.1, SHALL SEATTLE GENETICS OR SEATTLE GENETICS’ AFFILIATES BE LIABLE FOR INDIRECT, INCIDENTAL, LIQUIDATED OR CONSEQUENTIAL DAMAGES,
INCLUDING WITHOUT LIMITATION, LOST REVENUES OR PROFITS. If at any time any representation or warranty to Seattle Genetics’ knowledge is no longer accurate, Seattle Genetics will promptly notify Abbott of such fact. 
  
 13.2 Abbott Warranties. Abbott warrants to Seattle Genetics that Bulk
Drug Substance delivered to Seattle Genetics pursuant to this Agreement (other than pursuant to Section 6.1) shall have been manufactured pursuant to cGMPs, the Batch Records shall conform with the Bulk Drug Substance Specifications, shall have been
manufactured in compliance with this Agreement and all applicable laws and regulations and shall be free from defects in materials and workmanship. Abbott warrants to Seattle Genetics that it has, and shall maintain in compliance with applicable
laws and regulations during the Term, the facilities, equipment, personnel, licenses and patents and expertise necessary to fulfill its obligations hereunder. Abbott also represents and warrants that the Bulk Drug Product will not be adulterated or
misbranded, within the meaning of the U.S. Food, Drug & Cosmetics Act, or any comparable laws, rules or regulations of any non-U.S. jurisdiction, as a result of any act or omission of Abbott. In addition, if any Abbott Inventions are
incorporated into the manufacturing process of the Bulk Drug Substance, without Abbott obtaining Seattle Genetics’ written consent, Abbott warrants that, to Abbott’s knowledge, Seattle Genetics’ use of such Abbott Inventions shall not
infringe or conflict with any patent or other proprietary right of any Third Party and there is no claim or basis therefor that might impair the use of such Abbott Inventions by Seattle Genetics to manufacture Bulk Drug Substance. ABBOTT MAKES NO
OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO BULK DRUG SUBSTANCE. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT, ARE
HEREBY DISCLAIMED BY ABBOTT. NOTWITHSTANDING ANY PROVISION TO THE CONTRARY IN THIS AGREEMENT, IN NO EVENT, EXCEPT PURSUANT TO SECTION 14.2, SHALL ABBOTT OR ABBOTT’S AFFILIATES BE LIABLE FOR INDIRECT, INCIDENTAL, LIQUIDATED OR CONSEQUENTIAL
DAMAGES, INCLUDING WITHOUT LIMITATION, LOST REVENUES OR PROFITS. If at any time any representation or warranty to Abbott’s knowledge is no longer accurate, Abbott will promptly notify Seattle Genetics of such fact. 
  
 In addition, (i) except as set forth in Section 14.2, Abbott shall not be
liable for any damages arising from claims of Third Parties for injury, death or property damage suffered as a result of the use of the Product, and (ii) in no event shall Abbott be liable for any claims relating to a failure of Abbott to warn, or
to adequately warn, against the dangers of the Product, or failure of Abbott to instruct, or to adequately instruct, about the safe and proper use of the Product or any 
  

					
	 CONFIDENTIAL AGREEMENT
	  	26	  	 

 use of the Product with any other product or products. Except as set forth in Section 14.2(i), the maximum liability of
Abbott under this Agreement for all claims, whether in connection with a warranty claim, an indemnity claim, a combination thereof, or otherwise and whether arising under contract, warranty, tort (including negligence), strict liability, product
liability, a combination thereof, or any other theory of liability or indemnification [***]. Seattle Genetics further acknowledges that, except in cases of Abbott’s wanton, willful, or gross negligence, or pursuant to Section 14.2(i), any [***]

  
 14. Indemnification 
  
 14.1 Seattle Genetics Indemnification. Seattle Genetics shall defend,
indemnify and hold harmless Abbott, its Affiliates, and its permitted contractors and their respective employees, directors and agents against any Liability resulting from any Third Party demand, claim, action or lawsuit arising from or based on (i)
Seattle Genetics’ negligence or willful misconduct in the development, testing, use, manufacture, promotion, marketing, sale, distribution, packaging, labeling, handling, storage, and/or disposal of Bulk Drug Substance and/or formulations
containing Bulk Drug Substance or its raw materials; or (ii) alleged infringement of any patent or other proprietary rights of such Third Party based on the testing, use, manufacture, promotion, marketing, sale, distribution, packaging, labeling,
handling, storage, and/or disposal of the Bulk Drug Substance by Abbott, its Affiliates, and permitted contractors, except to the extent the Third Party demands, or lawsuit arises predominantly out of, or relates to the events described in Section
14.2 (ii); or (iii) Seattle Genetics’ and/or any Seattle Genetics’ Affiliate’s, licensee’s and/or sublicensee’s material breach of this Agreement, except to the extent the Third Party demand, claim, action or lawsuit arises
predominantly out of or relates to the events described in Section 14.2. 
  
 14.2 Abbott Indemnification. Abbott shall defend, indemnify and hold harmless Seattle Genetics, its Affiliates, licensees and sublicensees and their respective employees, directors and agents against any
Liability from any Third Party demand, claim, action or lawsuit arising from or based on (i) Abbott’s negligence or willful misconduct in the development, testing, use, storage, handling, packaging, labeling, manufacture, or delivery of Bulk
Drug Substance, formulations containing Bulk Drug Substance or its raw materials; (ii) any manufacturing procedures, methods or techniques (or component thereof) that are incorporated into the manufacturing process of the Bulk Drug Substance by
Abbott which Seattle Genetics did not provide written consent and are other than Seattle Genetics Patent Rights, Seattle Genetics Know-How and Seattle Genetics Inventions, or (iii) Abbott’s, its Affiliate’s, or its contractor’s
material breach of this Agreement, except to the extent the Third Party demand, claim, action or lawsuit arises predominantly out of or relates to the events described in Section 14.1. 
  
 14.3 Claims and Proceedings. Each Party shall notify the other promptly of any threatened or pending claim or
proceeding covered by any of the above Sections in this Article 14 and shall include sufficient information to enable the other Party to assess the facts; provided, 
  

					
	 CONFIDENTIAL AGREEMENT
	  	27	  	 

 however, the failure to provide such notice within a reasonable period of time shall not relieve the indemnifying Party
of its obligations hereunder except to the extent the it is prejudiced by such failure. Each Party shall cooperate in good faith with the indemnifying Party in the defense of all such claims, with the indemnifying Party being permitted to maintain
control of such defense through legal counsel selected by such Party. No settlement or compromise shall be binding on a Party hereto without its prior written consent. 
  
 15. Assignment 
  
 Neither Party may assign this Agreement or any of its rights under this Agreement or delegate (or subcontract) any of its duties or obligations under this
Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, but subject to the last sentence of this Article 15, either Party may assign
this Agreement, without the other Party’s consent, to any purchaser of all or substantially all of such Party’s assets, or to any successor by way of merger, consolidation or similar transaction. Subject to the foregoing, this Agreement
will be binding upon, enforceable by, and inure to the benefit of the Parties and their respective successors and assigns. It shall be deemed reasonable to withhold consent to an assignment of this Agreement in the event that such assignment would
materially impair or jeopardize any pending or actual regulatory approval for the manufacture of the Bulk Drug Substance or adversely affect the regulatory status of the Bulk Drug Substance or any Product. It shall be deemed reasonable for Seattle
Genetics to withhold consent to an assignment in the event that such assignment would have a substantial likelihood of (a) impairing or jeopardizing any pending or actual regulatory approval for the manufacture of the Bulk Drug Substance, (b)
adversely affecting the regulatory status of the Bulk Drug Substance or (c) materially delaying delivery schedules, increasing the pricing or adversely affecting the quality of the Bulk Drug Substance. 
  
 16. Notices 
  
 All notices hereunder shall be in writing and shall be delivered personally, by nationally recognized courier service,
registered or certified mail, postage prepaid, mailed by express mail service or given by facsimile (with hard copy sent by one of the other approved methods on the same day), to the following addresses of the respective Parties: 
  

			
	 If to Abbott:
	  	Abbott Laboratories
	 	  	Senior Vice President
	 	  	Global Pharmaceutical Manufacturing
	 	  	Department 390, Building NCA1
	 	  	1401 Sheridan Road
	 	  	North Chicago, IL 60064-6314
	 	  	Fax Number: 847-938-2315
		
	 with copy to:
	  	Abbott Laboratories
	 	  	Senior Vice President and General Counsel
	 	  	Department 364, Building AP6D
	 	  	100 Abbott Park Road
	 	  	Abbott Park, IL 60064-6049
	 	  	Fax Number: 847-938-6277

  

					
	 CONFIDENTIAL AGREEMENT
	  	28	  	 

			
	 If to Seattle Genetics:
	  	Seattle Genetics, Inc.
	 	  	Chief Executive Officer
	 	  	21823 30th Drive SE
	 	  	Bothell, WA 98021
	 	  	Fax Number: (425) 527-4109
		
	 with copy to:
	  	Seattle Genetics, Inc.
	 	  	General Counsel
	 	  	21823 30th Drive SE
	 	  	Bothell, WA 98021
	 	  	Fax Number: (425) 527-4109

  
 Notices shall be effective upon
receipt if personally delivered, on the third business day following the date of mailing if sent by certified or registered mail, and on the second business day following the date of delivery to the express mail service if sent by express mail, or
the date of transmission if sent by facsimile (provided a hard copy is sent as described above). A Party may change its address listed above by notice to the other Party. 
  
 17. Entire Agreement; Amendments 
  
 This Agreement constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all written or oral prior
agreements or understandings with respect thereto, including, without limitation, that certain [***] between Abbott and Seattle Genetics. No amendment or modification to this Agreement will be effective unless it is in writing and signed by
authorized representatives both Parties to this Agreement. 
  
 18. Alternative
Dispute Resolution and Applicable Law 
  
 18.1 Choice of
Law. This Agreement shall be construed, interpreted and governed by the laws of the State of Illinois, excluding its choice of law provisions. 
  
 18.2 Alternative Dispute Resolution. The Parties recognize that bona fide disputes may arise which relate to the Parties’ rights and
obligations under this Agreement. The Parties agree that any such dispute shall be resolved by Alternative Dispute Resolution (“ADR”) in accordance with the procedure set forth in Exhibit E. 
  
 19. Force Majeure 
  
 Any delay in the performance of any of the duties or obligations of any Party (except the payment of money due hereunder for
services rendered) caused by an event outside the affected Party’s reasonable control shall not be considered a breach of this Agreement, and unless provided to the contrary herein, the time required for performance shall be extended for a
period equal to the period of such delay. Such events shall include without limitation, acts of God; acts of the public enemy; insurrections; riots; terrorism, injunctions; embargoes; labor disputes, including strikes, lockouts, job actions, or
boycotts; fires; explosions; floods; earthquakes; 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	29	  	 

 shortages of material or energy; delays in the delivery of raw materials, or other unforeseeable causes beyond the
reasonable control and without the fault or negligence of the Party so affected (a “Force Majeure Event”). The Party so affected shall give prompt notice to the other Party of such cause, following which the Parties will promptly
meet to determine an equitable solution to the effects of such event and the Party affected by the event shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. Seattle Genetics may
cancel without penalty (and shall have no obligation to pay any amounts attributable to minimum quantities or firm Purchase Orders applicable to any period following the date of the Force Majeure Event) (a) any and all Purchase Orders in the event
Abbott is unable to fulfill an outstanding Purchase Order within sixty (60) days of its scheduled delivery date due to a Force Majeure Event and (b) this Agreement if the Force Majeure Event affects Abbott’s ability to perform pursuant to this
Agreement for more than an aggregate of one hundred twenty (120) days in any single Contract Year or any consecutive period of ninety (90) days. Upon cessation of such Force Majeure Event, the affected Party shall promptly resume performance on all
Purchase Orders which have not been terminated. 
  
 20. Severability

  
 If any term or provision of this Agreement shall for any
reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and in lieu of each such invalid, illegal or unenforceable provision there shall be
added automatically as a part of this Agreement a provision that is valid, legal and enforceable, and as similar in terms to such invalid, illegal or unenforceable provision as may be possible while giving effect to the benefits and burdens for
which the Parties have bargained hereunder. 
  
 21. Waiver 
  
 No waiver or modification of any of the terms of this Agreement shall be
valid unless in writing and signed by an authorized representative of each Party hereto. Failure by either Party to enforce any rights under this Agreement shall not be construed as a waiver of such rights, nor shall a waiver by either Party in one
or more instances be construed as constituting a continuing waiver or as a waiver in other instances. 
  
 22. Exhibits 
  
 All
Exhibits referenced herein are hereby made a part of this Agreement. 
  
 23.
Counterparts 
  
 This Agreement may be executed in any
number of separate counterparts, each of which shall be deemed to be an original, but which together shall constitute one and the same instrument. 
  
 24. No Publicity 
  
 Except as required by law or regulation, neither Party shall disclose any of the provisions of this Agreement or make any public announcement or public
statement concerning this 
  

					
	 CONFIDENTIAL AGREEMENT
	  	30	  	 

 Agreement or its subject matter, without the prior written approval of the other Party; provided, however, that with
regard to any such disclosure, announcement or statement that is required by law or regulation, the disclosing Party shall submit the proposed disclosure, announcement or statement in writing to the other Party at least ten (10) days prior to the
date of making such disclosure, announcement or statement and shall, in good faith, give reasonable consideration to any comments proposed by such other Party. Notwithstanding the foregoing, either Party, without the consent of the other Party, may
disclose the general nature and terms of this Agreement to third parties in connection with financings, corporate partnering transactions or M&A discussions, provided that prior to such disclosure, such third parties executed confidentiality and
non-disclosure agreements with terms no less stringent than as provided for in Article 11. 
  
 25. Relationship 
  
 The
relationship between the Parties to this Agreement is that of independent contractors and nothing herein shall be deemed to constitute the relationship of partners, joint ventures, nor of principal and agent between Abbott and Seattle Genetics.
Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any contract or undertaking with any Third Party. 
  
 26. Headings 
  
 The headings in this Agreement are for convenience of reference only and shall not affect its interpretation. 
  
 27. Insurance 
  
 During the Term, Seattle Genetics and Abbott shall maintain in full force and effect, for the benefit of Seattle Genetics
and Abbott respectively product liability insurance (with Abbott’s coverage extending to its obligations as a manufacturer of the Bulk Drug Substance) in an amount of not less than [***] for each accident or occurrence and in the aggregate. At
the inception of this Agreement and annually thereafter, Seattle Genetics and Abbott shall furnish the other with a certificate of insurance evidencing that it has such insurance coverage in force. During the Term, either Party may self-insure in
whole or in part the insurance requirements described above, provided such Party maintains both (a) a net worth as measured by its retained earnings in the amount of [***] and (b) a minimum of [***] of unrestricted cash or cash equivalents at its
disposal (together, “Self-Insurance Requirement”). If a Party self-insures in accordance with the foregoing, then in order to be permitted to maintain such self-insurance, such Party must maintain throughout the Term the
Self-Insurance Requirement and deliver to other Party, within [***] after the end of each of such Party’s fiscal years, a statement in the form described above evidencing the compliance with the Self-Insurance Requirement. If at any time the
Party fails to comply with either of the Self-Insurance Requirement, then such Party must obtain, provide, and keep in full force and effect (until the Party complies with Self-Insurance Requirements) the above referenced insurance coverage and
provide the other Party with evidence of the same in accordance with this Section. Notwithstanding any of the foregoing to the contrary, so long as a Party is publicly traded on a nationally recognized stock exchange, such 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	31	  	 

 Party shall have no obligation to provide the other Party with documentation which evidences compliance with the Self
Insurance Requirement as otherwise required pursuant to this Section. 
  
 28.
Debarment 
  
 Each of the Parties warrants and represents
to the other Party that each such Party has never been, is not currently, and, during the Initial Term and the Term, will not become, a Debarred Entity, Excluded Entity or Convicted Entity. Each of the Parties further warrants and represents that no
Debarred Individual, Debarred Entity, Excluded Individual, Excluded Entity, Convicted Individual or Convicted Entity has performed or rendered, or will perform or render, any services or assistance on its behalf relating to activities taken pursuant
to this Agreement. If any of the foregoing warranties or representations becomes untrue as to a specific Party (by way of example only, if Abbott or any individual or entity performing services on its behalf hereunder becomes excluded, debarred or
suspended after the Effective Date of this Agreement), such Party shall immediately notify the other Party and this shall constitute grounds for immediate termination by the Party which has not violated the representations and warranties of this
Section. This provision shall survive termination or expiration of this Agreement. 
  

					
	 CONFIDENTIAL AGREEMENT
	  	32	  	 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized
representatives on the later day and year written below. 
  

									
	 ABBOTT LABORATORIES
	 	 	 	 SEATTLE GENETICS, INC.

					
	By:	 	/s/    MIKE L. MCGIBBON
        	 	 	 	By:	 	/s/    CLAY B. SIEGALL        
	 	 	 Mike L. McGibbon
  
 Title: General Manager, Pharma
  
 Date:            2/18/05            
	 	 	 	 	 	 Clay B. Siegall
  
 Title: President and Chief Executive Officer
  
 Date:            2/18/05            

  

					
	 CONFIDENTIAL AGREEMENT
	  	33	  	 

 EXHIBIT A 
  
 Bulk Drug Substance 
  
 SGN-40 is a humanized mAb directed against human CD40 expressed [***]. 
  
 SGN-40 has a structure comparable to [***]. 
  
 [***] 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	34	  	Abbott-Seattle Genetics

 EXHIBIT B 
  
 Preliminary SGN-40 Purified Bulk Drug Substance Specifications 
  
 [***] 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	35	  	Abbott-Seattle Genetics

 EXHIBIT C 
  
 Seattle Genetics (SGEN) – Abbott Bioresearch Center (ABC) 
 SGN-40 Project 
  
 [***]

  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	36	  	Abbott-Seattle Genetics

 EXHIBIT D 
  
 [***] 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	37	  	Abbott-Seattle Genetics

 EXHIBIT E 
  
 Alternative Dispute Resolution 
  
 The Parties recognize that bona fide disputes as to certain matters may arise from time to time during the Term which relate to either Party’s rights and/or
obligations. To have such a dispute resolved by this Alternative Dispute Resolution (“ADR”) provision, a Party first must send written notice of the dispute to the other Party for attempted resolution by good faith negotiations
between their respective presidents (or their designees) of the affected subsidiaries, divisions, or business units within [***] after such notice is received (all references to “days” in this ADR provision are to calendar days).

  
 If the matter has not been resolved within [***] of the notice of dispute, or
if the Parties fail to meet within such [***], either Party may initiate an ADR proceeding as provided herein. The Parties shall have the right to be represented by counsel in such a proceeding. 
  

	1.	To begin an ADR proceeding, a Party shall provide written notice to the other Party of the issues to be resolved by ADR. Within [***] after its receipt of such notice, the other
Party may, by written notice to the Party initiating the ADR, add additional issues to be resolved within the same ADR. 

  

	2.	Within [***] following receipt of the original ADR notice, the Parties shall select a mutually acceptable neutral to preside in the resolution of any disputes in this ADR
proceeding. If the Parties are unable to agree on a mutually acceptable neutral within such period, either Party may request the [***]: 

  

	 	(a)	The CPR shall submit to the Parties a list of not less than [***] within [***] after receipt of the request, along with a [***]. [***]. 

  

	 	(b)	Such list shall include a statement of disclosure by each [***] of any circumstances likely to [***]. 

  

	 	(c)	Each Party shall number the [***] in order of preference (with the number one (1) signifying the greatest preference) and shall deliver the list to the [***] within [***] following
receipt of the list of [***]. If a Party believes a [***]. Any Party failing to return a list of preferences on time shall be deemed to have no order of preference. 

  

	 	(d)	If the Parties collectively have identified fewer than [***] deemed to have conflicts, the CPR immediately shall designate as the neutral the candidate for whom the Parties
collectively have indicated the greatest preference. If a tie should result between [***], the CPR may designate either candidate. If the Parties collectively have identified [***] or more candidates deemed to have conflicts, the CPR shall review
the explanations regarding conflicts and, in its sole discretion, may either (i) immediately designate as the neutral the candidate for whom the Parties collectively have indicated the greatest preference, or (ii) issue a new list of not [***], in
which case the procedures set forth in subparagraphs 2(a) – 2(d) shall be repeated. 

  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	38	  	Abbott-Seattle Genetics

	3.	No earlier than [***] or later than [***] after selection, the neutral shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take
place at a location agreed upon by the Parties. If the Parties cannot agree, the neutral shall designate a location other than the principal place of business of either Party or any of their subsidiaries or affiliates. 

  

	4.	At least [***] prior to the hearing, each Party shall submit the following to the other Party and the neutral: 

  

	 	(a)	a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the neutral; 

  

	 	(b)	a list of any witnesses such Party intends to call at the hearing, and a short summary of the anticipated testimony of each witness; 

  

	 	(c)	a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not
contain any recitation of the facts or any legal arguments and shall not exceed one (1) page per issue. 

  

	 	(d)	a brief in support of such Party’s proposed rulings and remedies, provided that the brief shall not exceed [***] pages. This page limitation shall apply regardless of the
number of issues raised in the ADR proceeding. 

  
 Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents. 
  

	5.	The hearing shall be conducted on [***] consecutive days and shall be governed by the following rules: 

  

	 	(a)	Each Party shall be entitled to [***] of hearing time to present its case. The neutral shall determine whether each Party has had the [***] to which it is entitled.

  

	 	(b)	Each Party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence, to cross-examine witnesses, and
to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the Party conducting the cross-examination. 

  

	 	(c)	The Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address not only issues it raised but also any issues raised by the
responding Party. The responding Party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments
shall proceed in the same sequence. 

  

	 	(d)	Except when testifying, witnesses shall be excluded from the hearing until closing arguments. 

  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	39	  	Abbott-Seattle Genetics

	 	(e)	Settlement negotiations, including any statements made therein, [***] Affidavits prepared for purposes of the ADR hearing also [***]. As to all other matters, the neutral shall have
sole discretion regarding the [***]. 

  

	6.	Within [***] following completion of the hearing, each Party may submit to the other Party and the neutral a post-hearing brief in support of its proposed rulings and remedies,
provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 

  

	7.	The neutral shall rule on each disputed issue within [***] following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the
Parties on each disputed issue but may adopt one Party’s proposed rulings and remedies on some issues and the other Party’s proposed rulings and remedies on other issues. The neutral shall not issue any written opinion or otherwise explain
the basis of the ruling. 

  

	8.	The neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing Party (including all expert
witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: 

  

	 	(a)	If the neutral rules in favor of one Party on all disputed issues in the ADR, the losing Party shall pay [***]. 

  

	 	(b)	If the neutral rules in favor of one Party on some issues and the other Party on other issues, the neutral shall issue with the rulings a written determination [***]. [***].

  

	9.	The rulings of the neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having
jurisdiction. 

  

	10.	Except as provided in paragraph 9 or as required by law, the existence of the dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony,
proposed rulings, and briefs), and the rulings shall be deemed Confidential Information. The neutral shall have the authority to impose sanctions for unauthorized disclosure of Confidential Information. 

  

	11.	All disputes referred to ADR, the statute of limitations, and the remedies for any wrong that may be found, shall be governed by the laws of the State of [***].

  

	12.	The neutral may not award punitive damages. The Parties hereby waive the right to punitive damages. 

  

	13.	The hearings shall be conducted in the English language. 

  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	40	  	Abbott-Seattle Genetics

 EXHIBIT F 
  
 Dedicated Equipment 
  
 Anticipated Dedicated Equipment: 
  
 The Dedicated Equipment necessary to fully execute this Project, and in anticipation of commercial supply, will be mutually agreed to during the course of the Project.
The following is a list of anticipated Dedicated Equipment and associated cost: 
  
 [***] 
  
 Preliminary estimates for such equipment costs as of the
Effective Date are set forth below. If actual cost estimates vary during the course of the Agreement, Abbott shall notify and obtain approval from Seattle Genetics for such estimates prior to taking any action relative to their purchase. 

 
 [***]. 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	41	  	Abbott-Seattle Genetics

 EXHIBIT G 
  
 Seattle Genetics United States Patent Rights 
  
 [***] 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	42	  	Abbott-Seattle Genetics

 EXHIBIT H 
  
 Quality Agreement 
  
 [***] 
  

	
	  
 [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
  

  

					
	 CONFIDENTIAL AGREEMENT
	  	43	  	Abbott-Seattle Genetics

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]